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ABSTRACT

Impact of Neurodevelopmental Genes on the Trajectory of ADHD severity: A Pilot Study
by
Agnieszka Mlodnicka
Advisor: Dr. Jeffrey Halperin
Attention-deficit/Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder characterized
by symptoms of inattention and hyperactivity, and is associated with delays in neural development. To
assess the association of genes involved in neurodevelopment with symptoms and trajectory of ADHD,
saliva was collected and genotyped from 145 participants from a longitudinal study of preschoolers who
were followed annually for 7 years. We examined four single nucleotide polymorphisms (SNPs) in genes
associated with neurodevelopment: neuregulin-1 (NRG-1; SNP rs3924999), neurotropin-3 (NT-3; SNP
rs6489630), brain-derived neurotrophic factor (BDNF; rs6265), and regulator of G protein signaling 4
(RGS4; rs951439). Hierarchical linear modeling revealed that neuregulin-1 and neurotropin-3 were
associated with symptoms of inattention and hyperactivity at age 3-4 and throughout early childhood;
however, these genes did not impact the trajectory of the inattentive and hyperactive symptoms over
development. Early environmental factors such as maternal diabetes, maternal substance use (tobacco,
alcohol, illicit drug) were also analyzed along with each of the genetic factors. Maternal gestational
diabetes and NRG-1 risk allele, maternal gestational diabetes and BDNF, alcohol and NRG-1, and illicit
drug use and NT-3 were all associated with greater inattentive and hyperactive symptoms. Although the
sample size is small for a genetics study, these findings can inform future investigations in understanding
the neurodevelopment and heritability of ADHD.
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Attention-Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized
by inattention and/or hyperactivity/impulsivity above and beyond expected developmental and
situational levels (American Psychiatric Association [APA], 2013). ADHD is among the most common
diagnoses in childhood, affecting approximately 5% of school age children (APA, 2013). Symptoms of
ADHD emerge in early childhood and for some individuals continue through adolescence and adulthood.
Epidemiological studies indicate a higher proportion of boys diagnosed with ADHD than girls (Lahey,
Miller, Gordon, & Riley, 1999). In clinical settings, boys are six to ten times more likely to be referred for
clinical assessment (Willcutt & Pennington, 2000) and are three to four times more likely to meet
diagnostic criteria for the disorder compared to girls (Cantwell, 1996). Despite clear operational
diagnostic criteria for ADHD, children with the disorder are highly heterogeneous with regard to core
symptoms, comorbidity, associated features, and life-span trajectories, and this heterogeneity has
contributed to hindering research and understanding the underlying pathophysiology of the disorder.
ADHD is a heterogeneous condition
The ADHD diagnosis is divided into three presentations, predominantly inattentive,
predominantly hyperactive/impulsive, and combined (APA, 2013). To meet diagnostic criteria for the
inattentive or hyperactive/impulsive presentation, children need to display at least six out of nine
possible symptoms from each category, respectively. To meet criteria for the combined presentation,
children need at least six symptoms in both categories. Symptoms also need to be present in multiple
settings, most commonly at home and school, and result in functional impairment. Notably, girls who
are diagnosed with ADHD are more likely to exhibit inattentive symptoms while boys are more likely to
exhibit symptoms of hyperactivity and impulsivity (Levy, Hay, Bennett, & McStephen, 2005; Biederman
et al., 2002). The varying presentations and possible variation in the number and types of symptoms
results in a clinically heterogeneous presentation of the disorder across individuals.
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While ADHD most commonly emerges during the preschool and early school-age years, the
trajectory of the disorder and type of presentation over time is also highly variable. Some individuals
continue to meet criteria for the diagnosis through adolescence and adulthood, while other individuals
show a remittance of the disorder (Campbell, 1995; Connor, 2002). Approximately 30-50% of childhood
cases of ADHD remit by adolescence (Halperin, Trampush, Miller, & Newcorn, 2008) while remittance
increases to as high as 85% by the age of 25 years (Faraone, Biederman, & Mick, 2006). Some data
indicate an overall decline in symptoms of hyperactivity/impulsivity and inattention with age
(Biederman, Mick, & Faraone, 2000), while other data suggest that symptoms of
hyperactivity/impulsivity decrease over time while symptoms of inattention persist (DuPaul & Stoner,
2004; Wolraich et al., 2005). During preschool, children are more likely to be diagnosed with ADHDHyperactive/Impulsive Type, and as they reach school-age they are more likely to be diagnosed with
ADHD - Combined Type (Lahey, Pelham, Loney, Lee, & Willcutt, 2005). Furthermore, children who meet
criteria for ADHD – Combined Type are more likely to continue to meet criteria the disorder in later
development compared to those that meet for Inattentive or Hyperactive/Impulsive Subtype (Hart,
Lahey, Loeber, Applegate, & Frick, 1995). The lack of stability of symptom presentation and varying
developmental trajectories contribute to the heterogeneity of the disorder.
In addition, children with ADHD are likely to display a wide range of comorbid psychiatric
disorders. Among children with ADHD, as many as 70 – 80% meet diagnostic criteria for least one other
psychiatric disorder, with many meeting criteria for multiple disorders, including other
externalizing/behavioral as well as mood and anxiety disorders (Biederman, Newcorn & Sprich, 1991).
Although children with ADHD are likely to exhibit many psychiatric disorders, most comorbidity is with
other behavioral disorders. As many as half of children with ADHD meet criteria for Oppositional
Defiant Disorder (ODD) or Conduct Disorder (CD) (Swanson et al., 2001), with boys being more likely to
exhibit these comorbid externalizing behaviors (Abikoff et al., 2002; Gaub & Carlson, 1997). Yet
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internalizing mood and anxiety disorders are not uncommon, reaching a 25% prevalence rate, often in
combination with comorbid externalizing disorders (Schatz & Rostain, 2006).
In addition to psychiatric comorbidities, compared to their typically-developing peers, children
with ADHD have difficulties with social adjustment and social functioning (DuPaul, McGoey, Eckert &
VanBrakle, 2001; Pfiffner, Calzada, & McBurnett, 2000), elevated rates of language (Helland, Posserud,
Helland, Heimann, & Lundervold, 2012) and motor impairments (Fliers et al., 2008; Buitelaar, 2008), and
are more likely to underachieve academically (Marshall, Hynd, Handwerk & Hall, 1997). A recent metaanalysis of comorbid learning disability and ADHD revealed a mean comorbidity rate of 45.1%, which
included writing disorders, reading and/or math disabilities (DuPaul, Gormley, & Laracy, 2013). The
extremely high rates of comorbid disorders and functional difficulties further contribute to the
heterogeneous profile of symptoms and patterns of functioning among children with ADHD.
Biological Factors and ADHD
Research attempting to elucidate the etiology of ADHD has focused largely on genetic and
neurodevelopmental factors, although it is clear that environmental influences are also important.
Family studies have shown that biologically related family members of hyperactive children were more
likely to have hyperactivity than adoptive relatives (Morrison & Stewart, 1973), and rates of ADHD are
higher among biological relatives of adopted ADHD children compared to adopted relatives (Sprich,
Biederman, Crawford, Mundy & Faraone, 2000). Family studies rely on concordance of disease
presentation from parents to off-spring, and presence of disease among related siblings. A compilation
of twin studies from the United States and Europe indicated that the mean heritability estimate of ADHD
was .76, identifying ADHD as among the most heritable psychiatric disorders (Faraone et al., 2005).
Although family and twin studies have indicated high heritability, as discussed in detail below, molecular
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genetics studies have had very limited success in identifying specific genes that contribute to the
expression of the phenotype.
From a neurodevelopmental perspective, ADHD is associated with abnormalities in brain
anatomy, connectivity, and neurotransmitter function. Neuroimaging studies have indicated that
children with ADHD have a delay in cortical maturation in frontal, striatal, parietal and cerebellar
regions, with the most prominent delays in the prefrontal cortices (Castellanos et al., 2002a; Shaw et al.,
2007). Individuals with ADHD have deficits in cortical gray matter, and decreases in volumes and cortical
thickness of many brain regions, such as the superior frontal and orbital frontal cortex, anterior
cingulate and inferior frontal cortex (Amico, Stauber, Koutsouleris & Frodl, 2011). Childhood ADHD and
the persistence of ADHD in adulthood is associated with under activation of the lateral inferior frontostriatal and ventromedial frontostriatal networks involved in attention and motivation (Cubillo, Halari,
Smith, Taylor & Rubia, 2012; Konrad et al., 2010).
Based largely on the pharmacological effects of stimulant medications, it has been suggested
that catecholaminergic neurotransmitters, namely dopamine (DA) and noradrenalin (NA), are involved
in the etiology of ADHD (Noble, 2003). DA and NA activity in the prefrontal cortex appears to modulate
higher cognitive executive functions, such as working memory, which is the ability to transiently hold
and manipulate information necessary for generating forthcoming action (Durstewitz & Seamans, 2002).
As children with ADHD have often been shown to be deficient in these cognitive functions (Willcutt,
Doyle, Nigg, Faraone & Pennington, 2005), brain architecture and connectivity in these regions have
been posited to play a role in the etiology of ADHD.
ADHD is associated with areas of neuropsychological impairment which have also been posited
to be a contributing factor to the disorder’s etiology. Individuals with ADHD show deficiencies in
executive functioning (EF) including effortful attention (Douglas, 1983), inhibitory control (Barkley,
Grodzinsky, & DuPaul, 1992; Nigg, 2001; Schachar & Logan, 1990; Sergeant & Scholten, 1985), working
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memory (Karatekin & Asarnow, 1998; Mariani & Barkley, 1997; Tannock, 1998), planning or set shifting
(Harrier & DeOrnellas, 2005; Nigg, Hinshaw Carte, & Treuting, 1998), and delay aversion (Sonuga-Barke,
2003). Poor inhibitory control, the ability to completely and suddenly stop an activity or planned course
of action (Logan & Cowan, 1984), has been linked to difficulties in working memory, self-regulation,
internalization of speech and behavioral analysis and synthesis (Barkley, 1997). However, only about
half of children with ADHD have EF deficits and any specific type of EF deficit (e.g., working memory,
inhibitory control, etc.) is present in even a smaller proportion of diagnosed children (Nigg, Willcutt,
Doyle & Sonuga-Barke, 2005). Thus, differences in profiles of neuropsychological functioning are an
additional source of heterogeneity in ADHD.
Genetics of ADHD
Despite compelling twin, adoption and family study evidence for the high heritability of ADHD,
molecular studies have not been very successful in identifying specific genes that account for this
heritability. Although limited and inconsistent, significant results in candidate gene research have
implicated several genes involved in neurophysiological processes which are associated with ADHD. The
following will be a brief review of findings.
Dopamine System Genes
DA is a neurotransmitter, which has been posited to be associated with the etiology of ADHD,
along with an array of other psychiatric and neurological disorders (e.g., alcohol use, nicotine use,
substance use, mood disorders, posttraumatic stress disorder, schizophrenia, bipolar disorder,
movement disorders, migraines) (Noble, 2003). Interest in DA’s purported role in the pathophysiology
of ADHD initially emerged from the mechanism of action of pharmacological treatment of ADHD. Firstline treatment for ADHD often involves psychostimulants, such as methyphenidate and ampthetamine,
which have been found to be efficacious for most individuals for the short-term reduction of ADHD

NEURODEVELOPMENTAL GENES ADHD

6

symptoms (Castellanos & Tannock, 2002b). Both methylphenidate and amphetamine increase the
amount of dopamine in the synapse through somewhat different mechanisms. Methyphenidate blocks
the reuptake of DA by the DA transporter, while amphetamine causes the DA transporter to be
internalized (Saunders et al., 2000). Blocking the DA transporter and decreasing the number of DA
transporters results in the increase of dopamine within the synapse (Kuczenski & Segal, 1997; Segal &
Kuczenski, 1999; Volkow et al., 2002). Stimulants differentially increase dopamine release in the
prefrontal cortex with minimal effects on subcortical brain regions (Berridge et al., 2006). This increase
in synaptic levels of DA, in turn, is believed to enhance executive functioning by way of frontostriatal
pathways (Swanson, Kinshourne, Nigg, Lanphear, Stefanatos, et al., 2007). The use of stimulant
medication in the psychopharmacological treatment of ADHD and the involvement of the DA pathway in
the mechanism of action of stimulants implicate DA as a possible source of ADHD pathophysiology, and
has led to considerable interest in studying DA system genes as candidates for explaining the genetic
basis of ADHD.
There are multiple points of interest along the DA pathway which can be implicated in the
etiology of ADHD, and research has focused on several genes involved in the regulation of DA. One
often studied candidate gene is the dopamine 4 receptor gene (DRD4). The DRD4 gene has several
alleles, which present in distinct variable number tandem repeat (VNTR) polymorphisms. The most
prevalent are the 2, 4 and 7-repeat alleles. Research has primarily focused on the 7-repeat allele of
DRD4, which has been hypothesized to increase the risk for ADHD (Faraone, Doyle, Mick & Biederman,
2001). Functionally, the 7-repeat allele results in a receptor, which is less sensitive to DA, reducing the
formation of cyclic AMP (Asghari et al., 1995). Results of studies examining the associations between
the 7-repeat allele and ADHD have not been consistent, and no single study has indicated a significant
association between the 7-repeat allele and ADHD. Nevertheless, when results of multiple studies were
pooled, an overall significant, but small effect, was noted. The odds ratio (OR) for case-control studies
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was 1.9 (p < 0.001), and for family-based studies was 1.4 (p = 0.02) (Faraone et al., 2005). Other DRD4
polymorphisms, the 2 and 4-repeat allele, have not demonstrated conclusive results (Kustanovich et al.,
2003). Although far from conclusive, results implicate the DRD4 7-repeat allele as a possible contributor
to the etiology of ADHD.
Also of potential interest is the dopamine receptor 5 (DRD5) gene. This receptor stimulates
adenylyl cyclase activity and is expressed in the limbic system of the brain. The limbic system is involved
in motivation and emotion, and is regulated by the prefrontal cortex (Kustanovich, et al., 2003). Results
from studies examining the association between DRD5 and ADHD have been inconsistent. Among three
alleles of interest, 148-bp, 136-bp, and 146-bp alleles, one study revealed an association with the 148-bp
allele, but not the 136-bp and 146-bp alleles (Barr et al., 2000). Similarly, two family-based studies of
association identified the 148-bp to be associated with ADHD (Payton et al., 2001). Four meta-analyses
indicated inconsistent results. Two indicated an association with the 148-bp allele and ADHD with an
(OR)=1.3 (Li, Sham, Owen, & He, 2006a; Lowe et al., 2004). The remaining two meta-analytic studies did
not find a relationship between the 148-bp allele and ADHD (Mill et al., 2005; Loo et al., 2003). Taken
together, one allele of the DRD5, the 148-bp allele, may be a source of possible association with ADHD,
but further investigation is needed.
Studies exploring the relations between the dopamine D2 receptor gene (DRD2) and ADHD have
focused on the A1 allele. Imaging results indicate that individuals with the DRD2 A1 allele compared to
those who do not have the allele, have a reduction in the number of D2 dopamine receptors and altered
binding characteristics (Thompson et al., 1997). The reduction in the number of D2 dopamine receptors
results in a decrease in various complex cognitive functions (Noble, 2003). One study supported the
association between the A1 allele and ADHD, with a positive relationship such that increased frequency
of the A1 allele was linked to greater severity of ADHD (Comings et al., 1996). In contrast, another study
found that a higher number of ADHD symptoms were associated with a decrease in the frequency of the
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A1 allele, while a positive correlation was found between the A2 allele and symptoms of hyperactivity
and impulsivity (Rowe, 1999). Although a possible source of association with ADHD, findings involving
DRD2 are inconsistent.
The Dopamine D1 Receptor (DRD1) is expressed in multiple brain areas with high expression in
the prefrontal cortex and striatum (Jin, Wang & Friedman, 2001). DRD1 is implicated in multiple
physiological functions such as regulation of neural growth and development (Arnsten, 2006; Paul,
Graybiel, David, & Roberston, 1992) in addition to regulating hyperactivity (Crawford, Drago, Watson, &
Levine, 1997) and attention (Arnsten, 2006). Two different case control samples found an association
with DRD1 in childhood combined type ADHD, but not in adulthood ADHD (Ribasés et al., 2012). Bobb
and colleagues (2005) found only two SNP alleles of the DRD1 gene to be significantly associated with
ADHD (rs4532, rs265981).
Other genes in the DA pathway have also been investigated as possible sources of ADHD
heritability. The dopamine transporter gene (DAT1) has been identified as a possible candidate due to
stimulant medication’s mechanism of action of blocking the dopamine transporter (Spencer et al.,
2012). Although one study found a significant association between DAT1 and the severity of ADHD
symptomology, most studies have failed to show association of DAT1 and ADHD, (Faraone et al., 2005;
Waldman et al., 1998; Franke et al., 2009; Spencer et al., 2012). Dopamine beta hydroxylase (DBH) is
the enzyme in the dopamine pathway, which converts dopamine to norepinephrine. The A1 and A2
alleles of the Taq 1 polymorphism of DBH were weakly but significantly associated with ADHD (Daly et
al., 1999; Roman et al., 2002; Smith et al., 2003). A small number of studies investigating the association
of Tyrosine Hydroxylase (TH), the enzyme involved in the synthesis of DA, with ADHD have not observed
any associations (Faraone et al., 2005). Additionally, the dopamine D3 receptor (DRD3) has not been
associated with ADHD (Brookes et al., 2006; Faraone et al., 2005; Guan et al., 2008). Overall, although
theoretically linked to ADHD via the mechanism of action of stimulant medications, studies of genes
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involved in the DA pathway have not been successful in consistently identifying specific genes in the DA
pathway, which are implicated in the heritability and etiology of ADHD.
Other genes involved in the catecholaminergic system have also been studied in relation to
ADHD. Catechol-O-methyltransferase (COMT) is involved in the degradation of catecholamines, such
as dopamine, epinephrine, and norepinephrine. Association with ADHD has been inconsistent, with
some studies showing significant association with the Val108Met polymorphism while other studies did
not show significant associations (Faraone et al., 2005). Monoamine Oxidase A (MAO-A) is an enzyme
involved in the degradation of norepinephrine, dopamine, and serotonin. Studies have shown
association with ADHD for the 30-bp tandem repeat of the promoter region of the gene in two ethnic
populations (Manor et al., 2001). Similar to DA genes, results of studies focusing on the associations
between other catecholaminergic system genes and ADHD are weak and inconsistent.
Noradrenergic (NA) System Genes
In addition to the suggestion of a role for the DA pathway in the etiology of ADHD,
pharmacological and neuroimaging studies also suggest the influence of the NA system. Besides acting
on DA, pharmacological interventions for ADHD also influence the noradrenergic system. Not only do
the stimulant medications have direct effects on central NA transmission that are analogous to their
effects on DA, but atomoxetine, an effective nonstimulant, inhibits the presnaptic NA transporter,
causing an increase in the release of monomaines (Popper, 2000). Further, guanfacine, another nonstimulant preparation approved for the treatment of ADHD, is a highly selective Alpha-2a agonist. Thus,
all medications that are effective for the treatment of ADHD have direct effects on the central NA
system. In addition to the pharmacological evidence, the NA system has important influences on the
prefrontal cortex (Asghari, et al., 1995; Berridge, et al., 2006), and the ascending NA pathways from the
brainstem to the prefrontal cortex play a role in executive functioning (Arnsten, 2006) and have been
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demonstrated to be responsible for maintaining alertness and attentional control (Aston-Jones,
Rajkowski & Cohen, 1999).
The three most investigated NA genes associated with ADHD are the noradrenaline transporter
(SLC6A2/NET1) and the three adrenergic receptors (ADRA1A, ADRA1B, and ADRA2B). An international
study of 51 candidate genes associated with ADHD reported a positive association with three NA system
genes: SLC6A2/NET1, ADRA1A and ADRA2B (Brookes et al., 2006). A subsequent meta-analysis did not
find the same associations (Gizer, Ficks, & Waldman, 2009). Most recently, a 91 SNP investigation by
Hawi and colleagues (2013a) did not find a significant association with SLC6A2/NET1, ADRA1A, ADRA1B
or ADRA2B genes; however significant associations with multi SNP haplotypes of SLC6A2/NET1 and
ADRA1B were found. These significant haplotype findings suggest a contribution of the NA system to
the etiology of ADHD, with a call for further investigation.
Studies investigating NA transporter and receptor SNPs in relation to ADHD have revealed
inconsistent results. Two studies found an association of a single SLC6A2 SNP (rs3785157), while only
one study found an additional SNP association (rs998424) (Xu et al., 2005a; Bobb et al., 2005). However,
Brookes and colleagues (2006) failed to replicate the same positive results; in contrast two additional
SNPs were found to be significant (rs3785143 and rs11568324). While one study found a significant
association between the G-1291C allele at the promoter region of the ADRA2A and ADHD (Comings et
al., 2003), other studies failed to find the same associations (Xu et al., 2001; Roman et al., 2003; Park et
al., 2004; Stevenson et al., 2005; Wang et al., 2006; Deupree et al., 2006). Similarly, results are
inconsistent when examining the relations with ADHD symptom dimensions. However, Schmitz and
colleagues (2006) found an association with the G-1291C allele exclusively in individuals with the
Inattentive Subtype of ADHD.
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Serotonergic System Genes
Although not as extensively investigated in the etiology of ADHD as catecholaminergic
neurotransmitter systems, evidence suggests that serotonergic activity is associated with impulsivity, a
key component of ADHD symptomatology (Oades, 2007). In addition, evidence suggests an interaction
between the serotonin and DA pathways, which regulates levels of both serotonin and DA (Oades,
2007). Therefore, a strong theoretical case can be made for a role for serotonin in the etiology of ADHD,
with a particular association with impulsivity.
Research on the role of serotonin in the genetic etiology of ADHD has largely focused on four
receptors (HTRIB, HTR2A, HTR1E and HTR3B). Three studies found a significant association of the HTR1B
receptor G861C allele with ADHD (Hawi et al., 2002; Quist et al., 2003; Smoller et al., 2006). A later
study did not find the same association (Heiser et al., 2007). The T102C and G1438A polymorphisms of
the HTR2A receptor have not been found to be significantly associated with ADHD (Zoroğlu et al., 2002).
Results of two family-based studies revealed conflicting findings, one study found an association for only
the His452Tyr allele and not the T102C allele (Quist et al., 2000) while another study did not find an
association with either of these alleles (Hawi et al., 2002). No significant associations were found with
the HTR1E and HTR3B receptors (Brookes et al., 2006).
The serotonin transporter has also been investigated as a source of ADHD etiology. The 5HTTLPR polymorphism located in the promoter region of the serotonin transporter gene (SLC6A4) has
been associated with ADHD in three case-control studies (Seeger, Schloss & Schmidet, 2001;
Retz,Thome, Blocher, Badder & Rösler, 2002; Zoroğlu et al., 2002), with one study not finding an
association (Beitchman et al., 2003). One family- based study found an association between the 5HTTLPR polymorphism and ADHD (Kent et al., 2002), while another study found an association with only
the combined type of ADHD (Manor et al., 2001). A third study did not find any association (Cadoret et
al., 2003). Family based studies failed to identify an association with the promoter allele (Banerjee et
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al., 2006; Kim et al., 2005; Li et al., 2007b; Xu et al., 2005b). In addition to the investigation of the 5HTTLPR allele of the promoter region, an intron polymorphism has also been investigated. One study
found a negative association with the allele (Banerjee et al., 2006), six studies found no association
(Brookes et al., 2006; Heiser et al., 2007; Kim et al., 2005; Wigg et al., 2006; Xu et al., 2005b), and Li and
colleagues (2007b) found a positive association.
The last area of interest in the serotonin pathway is tryptophan hydroxylase (TPH). TPH is a
rate-limiting enzyme, which synthesizes serotonin from tryptophan. Polymorphisms of TPH have been
associated with aggression and impulsivity (Manuck et al., 1999). Although two family-based studies did
not find an association between ADHD and the TPH gene, one study found an under transmission of a
haplotype consisting of two alleles in ADHD (Li et al., 2006b; Tang et al., 2001). A family-based study
found significant positive associations with three alleles; the rs1843809 T-allele, rs1386497 A-allele, and
rs1386493 C-allele (Sheehan et al., 2005). Brookes and colleagues (2006) also found positive
associations with ADHD, although for rs1843809 A-allele and rs1386493 G-allele. An association with
rs1007023 was not found by Sheehan et al. (2005). Overall, findings of associations between serotonin
system genes and ADHD suggest potential sources of genetic etiology, but further investigation is
warranted to clarify the findings.
Genes involved in neural plasticity and development
Due to evidence that ADHD is related to delayed brain growth and development (Shaw et al.,
2007), genes involved in neuronal growth and development have been theorized to play a role in the
pathophysiology of ADHD.
Synaptosomal-associated protein 25, kDA (SNAP25) is a protein found in the presynaptic plasma
membrane that is involved in the regulation of vesicular neurotransmitter release. SNAP25, in
combination with other proteins, forms a protein complex that is responsible for vesicle docking and
adhesion at the presynaptic membrane which triggers neurotransmitter exocytosis from the presynaptic
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membrane (Söllner et al., 1993). SNAP25 is also important for axonal growth and synaptic plasticity
(Osen-Sand et al., 1993). A mouse model with a deletion in the gene that encodes SNAP25 leads to
hyperactivity in the mice, along with compromised Ca++ dependent DA release in the dorsal striatum
(Wilson, 2000). Four family-based studies have examined two SNPs (T1069C and T1065G) in relation to
ADHD. Barr et al. (2000) found an association with the haplotype of the two alleles, while Kustanovich
and colleagues (2003) were not able to find the same association. Two studies with overlapping samples
found marginal associations (Mill et al., 2002; Mill et al., 2004). Pooled analysis for the T1065G SNP
showed significant evidence for an association with ADHD (Mick & Faraone, 2008). Analysis of two
family-based studies, indicated association with four out 12 of SNPs (rs66039806-C, rs362549-A,
rs362987-A, and the rs362998-C alleles) with one cohort, but not another cohort (Feng et al., 2005).
Although Brookes and colleagues (2006) did not evaluate the same SNPs as the previous study,
association with ADHD was found with rs363020 and rs362567. Analysis of the previously associated
SNPs in addition to five additional SNPs (rs6077699, rs363006, rs362549, rs362987, rs362998) found no
evidence of association with ADHD for any of the alleles (Kim et al., 2007). Moreover, pooled data
indicated modest association with two SNPs (rs3746544-T, rs6077690-T) (Kim et al., 2007). Expression
analysis indicated a significant association with one SNP (rs362990-A) and a haplotype of three SNPs
(rs6108461, rs362990 and rs362998) (Hawi et al., 2013b). Evidence implicated specific SNPs from
SNAP25 as being associated with ADHD.
One area of investigation has been the gene for brain-derived neurotrophic factor (BDNF), a
protein that is involved in the survival and differentiation of dopaminergic neurons in the developing
brain in addition to the stimulation of neuronal growth and differentiation. The Val66Met functional
polymorphism of the BDNF gene impacts intracellular trafficking and is involved in the activitydependent secretion of BDNF (Egan et al., 2003). Kent and colleagues (2005) found an association
between ADHD and paternal transmission of the Val66 allele of BDNF but not maternal transmission of
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the same allele. Xu and colleagues (2007) were not able to find the same results; in two family-based
studies they found an over transmission of a different allele, the C720T allele, in only one family cohort.
In contrast to the positive findings of the previous investigations, Brookes and colleagues (2006) failed
to find significant associations in 20 BDNF SNPs. Theoretically BDNF-related genes appear to be a
promising direction of research, although supportive evidence at this point is lacking.
Glutamate-related genes
Another area of investigation has involved glutamate receptors. Glutamate and N-methylD-aspartate (NMDA) receptors have been associated with cognition. A SNP of the glutamate receptor,
ionotropic, N-methyl D-aspartate 2A (GRIN2A) gene has been associated with ADHD in a family-based
study (Turic et al., 2004). Haplotype associations with additional SNPs in the same study were weak. A
subsequent family-based study found no association with the GRIN2A SNP or two novel SNPs (Adams et
al., 2004). Similar to the results of BDNF, this area is theoretically promising, but results are inconsistent
and need further investigation.
Genome-wide Association Studies
In contrast to hypothesis-driven studies of candidate genes, Genome-Wide Association Studies
(GWAS) investigate common genetic variants in the entire genome of individuals and relate those
variants to a specific trait. Investigations utilizing the GWAS approach focus on associations between
individual SNPs and ADHD. Neale and colleagues (2010) were the first to conduct a case-control GWAS
study on children and adolescents with ADHD. Of the over one million SNPs, which were analyzed in the
study, none met statistical significance. One of the SNPs located in the Protein Kinase, CGMPDependent 1 (PRKG1) gene was the closest to reaching significance. Results from a case-control GWAS
study conducted by Hinney et al. (2011) were similar, no SNP reached genome wide significance. A SNP
located on the Metabotropic Glutamate Receptor 5 (GRM5) gene was the best candidate for association.
A subsequent GWAS again did not find any significant associations, but the Cholinergic Receptor,
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Nicotinic, Alpha 7 (CHRNA7) receptor, was found to be the most promising (Stergiakouli et al., 2012).
Three family-based GWAS studies found no significant genome results (Neale et al., 2008; Lasky-Su et
al., 2008; Mick et al., 2010). Although results did not reach significance, both Lasky-Su et al. and Mick et
al. found SNPs associated with SLC9A9, an endosomal membrane protein gene involved in synaptic
transmission and plasticity, to be the closest to reaching significance. A large combined case-control
and family-based study also failed to find genome wide significance (Neale et al., 2010). Ebejer and
colleagues (2013) performed a meta-analysis of GWAS studies using the inattention and hyperactivity
symptom domains as continuous measures in the analysis. Although the methodological approach was
novel, results were similar to previous the GWAS studies, failing to show significant associations.
More recent GWAS studies have taken different approaches to find an association with ADHD.
In a departure from a typical GWAS approach that is not hypothesis driven, Bralten and colleges (2013)
showed an association between the three pathways of dopamine/norepinephrine, serotonin, and
neuritic out-growth genes and hyperactive/ impulsive symptoms and not inattentive symptoms.
Findings were not significant for multiple single gene SNPs, suggesting that the combined small effects
of multiple gene variants. Due to limited data from genome association studies it has been suggested
that biological processes such as, cell division, cell adhesion, neuronal migration, neuro plasticity, and
transcription, and the genetic processes that are involved in these processes are likely to be involved in
ADHD, in contrast to or in addition to dopaminergic, noradrenergic and serotonergic neurotransmitter
(Franke, Neale & Faraone, 2009). Like prior studies, a recent GWAS did not find genome-wide significant
SNPs associated with ADHD symptoms, however, there were three genes with high linkage detectability,
LMOD2, ASB15, and WASL (Middeldorp et al., 2016). One of the genes, WASL, is involved in cytoskeletal
organization during neuronal development, including long spine formation and neurite extension, which
seems to be the likely gene associated with ADHD. To increase the number of subjects Faraone (2016)
combined data sets from multiple studies using only participants of European decent. Analysis indicated
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significance with FOXP2, which has been shown to be associated with cognitive functioning,
development of language and speech, and expressed in the basal ganglia and inferior frontal cortex. A
GWAS study of glutamate genes indicated an association with hyperactivity/impulsivity severity, and
GABA genes were associated with inhibition, but only when corrected for genome-wide association
levels. It is important to note that a single gene was not found to be significant but rather gene sets in
tandem (Naaijen, et al., 2017).
An analysis of copy number variants (CNV) associated with biological pathways involved in
neurodevelopment were significant for respiratory electron transport, organonitrogen compound
catabolic process, transmembrane transporter activity, carbohydrate derivative catabolic process,
ligand-gated ion channel activity, ligand-gated ion channel activity, transmembrane transport, and iongated channel activity (Thapar et al., 2016). This further supports evidence for continued investigation
into neurodevelopmental pathways.
Summary of Genetic Findings and Conclusions
There are several possible explanations for the lack of positive and consistent molecular genetic
results in ADHD studies. One possibility is that ADHD is caused by single rare gene alleles, which have a
major determining effect on the likelihood of ADHD psychopathology. This possibility seems unlikely
given the prevalence of ADHD. Conversely, ADHD could be the result of multiple genes of very small
effect size with ADHD being the result of multiplicative gene effects or gene x gene interactions. Were
either of these the case, conventional approaches to genetic analysis would be unlikely to detect specific
genes related to the etiology of the disorder. Alternatively, it seems increasingly likely that ADHD is the
result of multiple etiologic pathways (Nigg, Willcutt, Doyle & Sonuga-Barke, 2005; Nigg, Nikolas,
Knottnerus, Cavanagh & Friderici, 2010; Sonuga-Barke, 2005). If this is the case and ADHD is
etiologically heterogeneous, attempting to gain an understanding of specific genes involved in the
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etiology of the disorder poses analytical difficulties and requires novel approaches to gene
identification. Summary of genetic findings can be located on Table 1 in the Appendix.
In contrast to conceptualizing ADHD as a unitary disorder based solely on meeting diagnostic
criteria for the disorder (yes/no), or even as distinct symptom dimensions of inattention and
hyperactivity/impulsivity, an alternative approach is to examine potential endophenotypes, which are
likely to be less genetically complex. Endophenotypes, the quantitative traits that impact an individual’s
risk to develop a disorder, can be meaningful sources of ADHD genetic etiology (Almasy & Blangero,
1998). Individuals with ADHD demonstrate phenotypic heterogeneity in terms of symptom severity,
mixture of symptoms, developmental course, comorbidity and cognitive performance. This phenotypic
variability may be the result of different genetic risks and etiological pathways. Moreover, research
focusing on endophenotypic refinement, such as cognitive performance, instead of more complex
dichotomous diagnoses or behavioral symptom dimensions, may lead to more precise findings in more
homogeneous subgroupings of the disorder.
Potential endophenotypes of ADHD based on aspects of executive functioning may mediate the
relations between the genetic risk and ADHD symptomatology. The literature suggests that between 3050% of children with ADHD have an executive function deficit (Loo et al., 2007; Nigg, Willcutt, Doyle, &
Sonuga-Barke, 2005). Executive functioning can include such neuropsychological constructs as working
memory, attention, planning, organization, inhibitory control, mental flexibility, initiation and selfmonitoring (Arnsten, 2006). Evidence of dysfunction in frontostriatal pathways, which play a key role in
executive functioning, has been reported in neuroimaging studies, eletrophysiological studies, and
neuropsychological assessment (Seidman, Valera & Makris, 2005; Chabot & Serfontein, 1996; Willcutt et
al., 2005).
In addition to its symptomatic and neurocognitive heterogeneity, ADHD also has tremendous
heterogeneity regarding the developmental course and outcome. One longitudinal study found that
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approximately half of 3- and 4-year-old children who presented with behavioral difficulties no longer
had symptoms at age 6 (Campbell, 1987). Others who used more rigorous diagnostic criteria for ADHD
found greater persistence from preschool to the school-age years, yet outcomes during childhood were
highly variable (Lahey, Pelham, Loney, Lee & Willcutt, 2005). This heterogeneity of course persists
throughout the lifespan with anywhere from 22 – 65% of children with ADHD having persistence of
symptoms into adolescence and adulthood (Barkley, Murphy, DuPaul & Bush, 2002; Biederman, Petty,
Evans, Small & Faraone, 2010; Halperin, Trampush, Miller, Marks & Newcorn, 2008; Klein et al., 2012;
Mannuzza et al., 2002).
While most genetic studies of ADHD have focused on the onset (presence vs. absence) of the
disorder or its associated symptoms, it has been hypothesized that the onset of ADHD and its
subsequent developmental trajectory, in particular as related to persistence and remittance, involve
distinct neural processes (Halperin & Schulz, 2006). Consistent with this idea, preliminary data suggest
that gene regulation might play a role in the divergent developmental trajectories of ADHD and that
genetic risk for ADHD can contribute to the developmental stability of the disorder. For example, Kuntsi
et al. (2005) found that children with ADHD who also had the DRD4 7-repeat allele were less likely to
persist with ADHD into middle childhood as compared to those without that allele. Further, children
with the 7-repeat allele had greater normalization of cortical thinning, higher IQ scores, and better
global functioning compared to children with ADHD who did not have the 7-repeat allele (Kuntsi et al.,
2005).
A British twin study found inter-individual differences in the developmental course of ADHD.
Hyperactive/Impulsive symptom severity was mostly explained by strong additive genetic influences,
while inattentive symptoms were associated with nonadditive genetic influence (dominant genetic
influence) (Pingault et al., 2015). This suggests that large genetic influences on the trajectory of ADHD
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symptoms are mostly specific and independent of those that account for variation in the baseline level
of symptoms.
Further, the developmental trajectory of ADHD may also be linked to gene expression. DNA
methylation, histone acetylation or methylation can regulate gene expression, which in turn influences
transcription activity and ultimately downstream expression of the gene product (Li et al., 2007a). Thus,
it is possible for gene expression to have a developmental course, with gene transcription varying across
development (Doyle et al., 2005). In addition to transcription factors, posttranscriptional factors such as
microRNAs are also involved in gene silencing (He & Hannon, 2004). MicroRNA’s have been shown to
regulate various developmental and physiological processes. The differential trajectory of ADHD across
development suggests that the role of gene regulation through external factors can play a role in the
remittance or persistence of ADHD.
Current voids in the understanding of ADHD and the plethora of inconsistent and largely
negative findings call for novel approaches to investigating the role of genes in ADHD. Further, the
dearth of studies that have considered the phenotypic heterogeneity or the role of development in this
highly heterogeneous neurodevelopmental disorder is striking. Clearly, further longitudinal research
focusing on the relations between genes and the developmental course/trajectory of ADHD is
warranted. Considering the heterogeneity of this disorder, the assessment of mediators and
moderators of the relations between genes and trajectory might yield particularly fruitful results.
Focusing on genes regulating monoamines closely associated with ADHD and frontostriatal systems in
the brain, such as the catecholamines, as well as brain growth and development might be a good place
to start.
Alternative Genetic Direction: Genes Associated with Neurodevelopment
As a developmental disorder, it is expected that genes associated with early neurodevelopment
would have a substantial role in the etiology and/or the trajectory of ADHD. Due to the absence of
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strong molecular genetic associations in the presence of strong heredity a genetic proposal of
alternative genes and SNPs is proposed. Given that ADHD is most likely related to many genes of small
effect size, it is likely that few or none of these genes alone will demonstrate a significant association
with the disorder. Rather, the combination of several genes might be more promising.
Neuroregulin-1
Neuroregulin-1 (NRG1), a pleotropic growth and differentiation factor, contributes to the
increase in the phosphorylation of tyrosine kinase (Falls, 2003). Studies on the functionally of NRG1
have observed that the gene is involved in the establishment and fine-tuning of cortical circuitry, and
synaptic efficacy. More specifically, in vitro studies demonstrated NRG1 to prompt the transcription of
mRNAs encoding neurotransmitter receptors (Ozaki et al., 1997), to modulate glutamatergic, GABAergic,
cholinergic, and dopaminergic neurotransmission (Gu et al., 2005; Ting et al., 2011; Woo et al., 2007),
and to promote dendritic spine growth (Cahill et al., 2013). Furthermore, dysregulation of expression
impaired synaptic plasticity, and overexpression of Ig-NRG1 in mice lead to synaptic dysfunction and
behavioral deficits, which included hyperactivity (Yin et al., 2013). Both increased and decreased
expression of the NRG1 has been associated with susceptibility to schizophrenia (Bertram et al., 2007;
Law et al., 2006, Yang, et al., 2003). NRG1 has been shown to be involved in multiple aspects of efficient
and effective neuronal formation, and is associated behavioral outcomes.
Neurotrophic factors: Neurotrophin-3 and Brain Derived Neurotrophic Factor
Neurotrophin-3 (NT-3) and Brain Derived Neurotrophic Factor (BDNF) are both essential for
neural growth, survival, and differentiation, and are therefore crucial for brain development. NT-3 and
BDNF both play a neuroprotective role against glutamate toxicity and glucose deprivation and neuronal
calcium homeostasis and protect neurons against metabolic/excitotoxic insults (Cheng & Mattson,
1994). Animal studies demonstrated that NT-3 and BDNF are expressed in the embryonic cortex, with
NT-3 expression decreasing as maturation progresses. In contrast BDNF is low in developing regions of
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the cortex and increases with maturation of the region (Maisonpierre, et al., 1990). Evidence shows that
both BDNF and NT-3 are involved in regulating the dendritic growth of pyramidal neurons in layer 4 of
the cerebral cortex, and NT-3 inhibits the dendritic growth stimulated by BDNF. In contrast, in layer 6 of
the cerebral cortex, BDNF inhibited dendritic growth stimulated by NT-3 (McAllister, Katz, & Lo, 1997).
Neurotrophins have also been investigated as mechanisms of synaptic plasticity, and long-term
functional and structural modification of synaptic connections (Poo, 2001). Primary alterations in the
activity of neurotrophins could lead to inappropriate alterations in cortical circuitry and synaptic
transmission in the developing brain, which could then lead into the neuronal dysfunction which
underlying psychiatric disorders such as schizophrenia (Favalli, Belmonte-de-Abreu, Wong, & Daskalakis,
2012).
NT-3 has been demonstrated to be involved in regulating central nervous system neurogenesis,
more precisely regulating aspects of early CNS development. In vitro studies corroborate the effects of
NT-3 on cell proliferation and differentiation, which are key regulators of neurogenesis in the CNS, which
can result in neuronal differentiation (Ghosh & Greenburg, 1995). A haplotype of NT-3 (rs4074967rs6332-rs6489630-rs7956189) was shown to be more associated with childhood ADHD compared to
adulthood ADHD and control (Ribasés, et al., 2008). NT-3 SNP rs6489630 has shown to be a protective
factor for Alzheimer’s Disease (Liu et al., 2016).
BDNF is involved in neurodevelopment, synapse regulation, and synaptic plasticity, it has been
proposed as a candidate to explain part of the pathogenesis of neurodevelopmental disease. BDNF has
been shown to modulate synaptic transmission (Levine, Dreyfus, Black, & Plummer, 1995). Adult BDNF
knockout mice have impaired hippocampal-dependent learning and long-term potentiation. In early
development, BDNF knockout mice exhibited hyperactivity and hippocampal learning deficits
(Monteggia, et al., 2004). BDNF SNP rs6265 has been shown to be involved in the pathophysiology of
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mood disorders and schizophrenia (Fernandes et al., 2014), and associated with parental reports of
ADHD symptoms (Gadow, et al., 2009).
Regulator of G protein signaling 4
Although less investigated than the prior genes, Regulator of G protein signaling 4 (RGS4), has
been implicated in dopamine expression and psychiatric illness. Specially, RGS4 SNP (rs951439) is one of
several SNPS being implicated in the clinical symptoms and antipsychotic treatment response of
schizophrenia, identifying RGS4 as a gene that contributes to the susceptibility of the disorder (Ding,
Styblo, Drobna, & Hegde, 2016). It is posited that one of the ways that RGS4 contributes to the etiology
is by influencing dopamine signaling, with RGS4 expression associated with cortical dopamine signaling
with COMT Val158Met genotype being associated with prefrontal along with hippocampal RGS4
expression (Lipska, 2006). RGS4 expression in the dorsolateral prefrontal cortex can also inhibit
dopamine D2 and D3 receptor signaling, while a decrease in RGS4 can increase D2 and D3 receptor
signaling (Min, 2012). Although there is not currently a direct link to suggest that RGS4 has a role in the
etiology of ADHD, there is a theoretical associated between similar neurotransmitter pathways.
Environmental Factors
In addition to genetic factors, several prenatal environmental factors have been shown to
influence neurodevelopment with some factors being associated with the development of ADHD.
Nicotine
Several studies have implicated prenatal nicotine exposure in the etiology of ADHD. A metaanalysis linked maternal and environmental nicotine exposure to signs of stress and nicotine withdrawal
following birth, presence of ADHD, and other externalizing outcomes, such as rule breaking and
aggressive behavior (Manzano et al., 2016). A retrospective study determined that children with ADHD
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were 2.1 times as likely to be exposed to nicotine during pregnancy compared to non-ADHD controls
(Mick, Biederman, Faraone, Sayer, & Kleinman, 2002). Additionally, a large Finish study revealed a
significant increase in ADHD in individuals exposed to maternal tobacco smoking (Joelsson et al., 2016).
Similarly, a large South Korean study of children born to mothers that smoked during pregnancy were
2.64 times more likely to be diagnosed with ADHD (Han et al., 2015). An investigation into the
neurocognitive and behavioral outcomes of children exposed to maternal smoking during pregnancy
showed lower verbal IQ, sluggish cognitive tempo on a measure of visual sustained attention (CPT),
more externalizing behaviors, emotional lability, restlessness/impulsivity, and visual working memory
deficiencies during school age (Thakur et al., 2013). The level of neuropsychological impairment had a
dose dependent impact. A recent Western Australian study found maternal smoking to a be a risk factor
for ADHD (Silva, Colvin, Hagemann, & Bower, 2013), and a large Danish study found that both maternal
and paternal smoking was associated with ADHD risk, with maternal smoking posing a higher risk, even
when the mother used nicotine replacement during pregnancy (Zhu et al., 2014). In contrast to these
studies Langley and colleges (2012) observed that both maternal and paternal smoking during
pregnancy was associated with ADHD symptoms, suggesting that the association with ADHD might be
more associated with heredity than prenatal environment.
Alcohol
Excessive maternal alcohol intake during pregnancy is associated with Fetal Alcohol Syndrome,
facial dysmorphology, growth restriction, and central nervous system/neurodevelopmental
abnormalities, which present as cognitive and social difficulties (Sokol, Delaney-Black, & Nordstrom,
2008). A Ukrainian study indicated that maternal alcohol consumption was associated with
neurodevelopmental deficits at 6 and 12 months (Bandoli, et al., 2016). A meta-analysis investigating
mild, moderate, and binge alcohol exposure during pregnancy found that binge consumption had a
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negative impact on cognition, and a moderate association with child behavior (Flack, 2013). Maternal
alcohol use during pregnancy was associated with increased ADHD risk 1.55 times, compared to mothers
that did not use alcohol during pregnancy (Han, et al., 2014). Children diagnosed with ADHD were 2.5
times as likely to be exposed to alcohol during pregnancy compared to non-ADHD controls (Mick,
Biederman, Faraone, Sayer, & Kleinman, 2002).
Illicit Drug Use
Research into maternal illicit drug use during pregnancy is limited, and due to the nature of the
substances used, are likely to be underreported. Nevertheless, literature on cannabis use during
pregnancy indicates adverse effects on neurodevelopment, especially during critical periods of brain
growth during fetal and adolescent maturation, such that children have long-term difficulties with visual
memory, executive functioning progressing through adolescence with aggression and attention
problems reported in preschool age children (Jaques et al., 2014). Children ages 1 and 3 with prenatal
exposure to methamphetamine had lower gross motor functioning, but not lower cognitive functioning
(Wouldes et al., 2014). Cocaine exposure during pregnancy has been associated with attention
difficulties in preschool and school age children (Leech, Richardson, Goldschmidt & Day, 1999; Bandstra,
Morrow, Anthony, Accornero, & Fried, 2001; Arendt, et. al, 2004; Savage, Brodsky, Malmud, Giannetta,
& Hurt, 2005). Illicit drug use in pregnancy has many confounds associated with the research.
Nevertheless, current literature does suggest long-term cognitive and behavioral effects associated with
exposure.
Maternal Gestational Diabetes
Maternal gestational diabetes has also been shown to be associated with ADHD. A
computerized measure of inattention, vigilance and perseveration (Conners CPT-II), did not show
differences. However, individuals born to women with gestational diabetes, were shown to have more
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psychopharmacological medication use for ADHD (Bytoff et al., 2017). A study following children born
to mothers with gestational diabetes, at 18-months had lower gross motor and expressive language
functioning (Torres-Espinola et al., 2015). A study of early infant development indicated that at 6 and
18-months there was greater inattention as indicated using an ERP paradigm (Cai et al., 2016). School
age children born to mothers with gestational diabetes showed fine and gross motor impairments and
difficulties with attention (Ornoy, Ratzon, Greenbaum, Wolf & Dulitzky, 2001). However, findings are
not consistent where one study showed that maternal obesity was associated with increases risk for
ADHD in preschool, maternal gestational diabetes was not (Daraki et al., 2017). Nomura and colleagues
demonstrated that maternal gestational diabetes and low SES accounted for a 2-fold increase in ADHD
diagnosis at 6 years (2012).
The Present Study
The aim of the current study is to examine the moderating effects of gene polymorphism on the
developmental trajectory of ADHD using hierarchical linear modeling. Participants in the current study
are a part of a larger established longitudinal study which has followed and evaluated children annually
from preschool to school age. During these annual evaluations, beginning at age 3-4 and continuing
until age 10, a parent diagnostic interview was conducted to determine ADHD symptom severity. The
moderating effects of four single nucleotide polymorphisms (SNPS) associated with neurodevelopment
and/or psychopathology were examined: neuregulin-1 (NRG-1; rs3924999), neurotropin-3 (NT-3;
rs6489630), brain-derived neurotrophic factor (BDNF; rs6265), and regulator of G protein signaling 4
(RGS4; rs951439). By using a novel longitudinal approach, rather than a single time point, allowed for a
more complete understand of the heterogeneity in the developmental trajectory of the disorder.
Taking reference from Rutter (1987) and the impact of psychosocial risk factors and the
interactive process of these factors on development, the current study examined the impact of prenatal
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environmental risk factors on ADHD symptom severity with the moderation of the chosen gene
polymorphisms and the prenatal environmental risk factors of maternal gestational diabetes, maternal
tobacco, alcohol and illicit drug use during pregnancy were examined.
Hypotheses
It was hypothesized that at risk-alleles of NRG-1, NT-3, BDNF, and RGS4, would be associated
with ADHD symptoms at preschool age. Additionally, it was hypothesized that the risk-alleles of NRG-1,
NT-3, BDNF, and RGS4 would be associated with persistence of ADHD symptoms until school age.
Finally, prenatal environmental factors (maternal gestational diabetes, maternal nicotine, alcohol and
illicit drug use) were explored as moderating factors of ADHD symptom severity at preschool age and at
school age.
METHOD
Participants
As part of larger longitudinal study examining factors associated with the persistence of ADHD
symptoms in preschoolers, a community-based sample of 3- and 4-year-old children were recruited. At
the initial recruitment permission form principals of local preschools was obtained to screen the school
for children with attention and behavior problems. Additional referrals from schools and clinicians were
also accepted. Entry into the study was based on parent and teacher reports on the home and school
version of the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV,
McGoey, DuPaul, Haley, & Shelton, 2007). Children who received 6 or more symptoms rated as “Often”
or “Very Often” on the Hyperactivity/Impulsivity and/or Inattention subscale(s) either by parent or
teacher were considered hyperactive/inattentive. Children who received fewer than 3 items rated as
“Often or Very Often” by both parents and teachers were expected into the study as Typically
Developing. Exclusion criteria were: Full Scale IQ < 80, as measured by the Wechsler Preschool and
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Primary Scale of Intelligence-Third Edition (WPPSI-III; Wechsler, 2002); evidence of a Pervasive
Developmental Disorder, Post-traumatic Stress Disorder or a diagnosed neurological disorder; nonEnglish-speaking parent or child; child not attending school; and treatment with systemic medication for
a chronic medical condition (including ADHD). The final sample for the longitudinal study was 216.
Among those, genetic data were successfully collected for the participants in this study, which consisted
of 145 children (109 boys) ranging in age from 3.00 to 4.92 years (M=4.22, SD=0.49) at the initial
evaluation (T1) and ranging in age from 10.37 to 12.51 years (M=11.43, SD=0.51) at the final evaluation
(T8). Of the 71 that were not included in the analysis, 48 were boys ranging in age from 3.19 to 5.00
(M=4.41, SD=0.44) at the first initial evaluation.
The sample was racially and ethnically diverse, comprising of 16 black (11.0%), 18 Asian (12.4%),
25 Hispanic (17.2%), 25 more than one race (17.2%), and 61 (42.1%) white children. Socioeconomic
status was assessed by the Occupational Prestige Scale (Nakao & Treas, 1994); the sample was largely
middle class (M=63.86, SD= 17.39) although a wide range was represented (range=20-97). (Sample
characteristic Table 2).
This study was approved by the Institutional Review Board of the university in which the
research was conducted. Following a complete description of the study, a parent of each child provided
written informed consent for participation.
Measures
Primary caregivers were interviewed at the baseline assessment (T1) and then annually to the
final measurement (T8) using the Kiddie Schedule for Affective Disorders and Schizophrenia – Present
and Lifetime Version (Kiddie-SADS-PL; Kaufman, Birmaher, Brent, Rao, & Ryan, 1996). The Kiddie-SADSPL is a commonly used diagnostic semi-structured interview that, when administered by trained
evaluators, has been shown to have strong psychometric properties (Kaufman et al., 1999). Diagnostic
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questions on the K-SADS-PL correspond to the 18 ADHD symptoms of ADHD. Each symptom was rated
as either 0 (symptom was not present), 1 (subthreshold symptom) to 2 (symptom present at diagnostic
level). The total score from all 18 symptoms provided the value for Total ADHD symptom severity. The
score from the 9 inattentive symptoms provided the value for the Inattentive symptom severity. The
score for the remaining 9 hyperactive/impulsive symptoms provided the value for the
Hyperactive/Impulsive symptom severity. When available, teacher rating on the school version of the
ADHD-RS-IV were incorporated to reach the final determination about each symptom at each time
point.
At the time of the baseline evaluation the caregiver completed an early developmental history
questionnaire that assessed prenatal risk factors. The caregiver indicated the presence of the following
during gestation: maternal gestational diabetes, maternal substance use (alcohol, tobacco, illicit drug
use).
Genotyping procedure
Genomic DNA was extracted from saliva (oragene•DNA, DNA Genotek, Inc, Ottawa, Ontario, Canada)
quantified on a spectrophotometer (NanoDrop ND-1000, NanoDrop, Wilmington, DE). A 1 ng DNA was
amplified in duplicate with a pre-designed TaqMan assay (assay ID C___1877332_20) according to the
manufacturer’s instructions (Thermo Scientific, Waltham, MA) and identified by measuring end-point
fluorescence on a LightCycler 480 II (Roche, Indianapolis, IN). Genotypes were determined for four
genes NRG1 (rs392499), NT-3 (rs6489630), BDNF (rs6265) and RGS4 (rs951439). The number of risk
alleles was calculated for each gene, and participants were categorized as either having no risk alleles or
at least one risk allele (1 or 2 risk alleles). A secondary analysis for the total number of risk gene alleles
was completed for NRG1, NT-3 and BDNF.
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Data Analysis
Due to the longitudinal nature of the data, varied ages of participants at the initial time point, and
missing values, Hierarchical linear modeling (HLM) was used at the primary statistical analysis. The
advantage of HLM is that it takes into account initial values beginning at different time points and
missing values. Therefore, in the current study, HLM can describe the growth curve of each individual’s
trajectory of ADHD symptom severity, collected yearly, across an 8-year period. HLM allows modeling
both within-and between-individual variations. At level-1, each individual’s data of ADHD symptom
severity was fitted into a regression line. Level-1 coefficients are empirical Bayesian estimates, which
are optimal estimates based on data from the individual and the entire sample. At level-2, the individual
genetic risk factors were entered to explain the between-subject variation in the intercept and the liner
slope.
To evaluate the longitudinal trajectory of ADHD symptom severity, the level-1 model was
defined, and then evaluated with level-2 predictors. At level-1, the linear model was tested for ADHD
symptom severity for three values: total, inattentive and hyperactive/impulsive symptoms. After the
level-1 model was determined, the genetic risk factors (for NRG-1, NTF3, BDNF, RGS4) were entered into
the model as level-2 variables, to determine if they explained a significant amount of the variance in the
mean intercept or slope. The intercept corresponded to the level of ADHD symptoms at the initial time
point, while the slope corresponded to change in ADHD symptom trajectory over the 8 time points.
To evaluate the impact of early prenatal environmental factors, a secondary analysis employed
independent samples t-tests to explore significant differences on ADHD Total symptom severity at the
final time point (T8). Lastly, regression analyses were used for the early environmental risk factors
(maternal gestational diabetes, maternal substance use (alcohol, tobacco, illicit drug use) in conjunction
with NRG-1, NTF3, and BDNF alleles.
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Table 2: Race and Ethnicity Characteristics
Frequency (%)
White

86 (59%)

Asian

18 (12%)

Black

16 (10%)

Other/Mixed

25 (17%)

Total

145

Not Hispanic

104 (72%)

Hispanic

41 (28%)

RESULTS
I. Gene Main Effects
Change in Total ADHD Symptom Severity
As shown in Table 3 and depicted in Figure 1, the estimated mean Total ADHD Symptom
Severity at 3-4 years was 17.08 (SE=0.94). The average slope or rate of change in ADHD severity over
time was -0.10 (SE=0.10). There was significant estimated variation around the intercept (χ2 = 1107.99,
df=144, p<0.001) and the slope (χ2 = 369.94, df=144, p<0.001). This indicates that the children varied
significantly in their Total ADHD Symptom Severity at age 3-4 and in their rate of change in Total ADHD
Symptom Severity over time.
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TABLE 3: Change in Total ADHD Symptom Severity over time
Results
Fixed Effects

Analysis
Coefficient

SE

T ratio

p

17.08

0.94

18.15

<0.001

-0.10

0.10

-0.96

0.34

χ2

p

Level 1 intercept
Intercept
Level 1 linear slope
Intercept

Random Effects
Level 1 intercept
Level 1 linear slope

Variance Component

df

112.22

144

1107.99

<0.001

0.98

144

369.94

<0.001

FIGURE 1
Model 1: Trajectories of Total ADHD Symptom Severity from ages 3 to 11 years.

Figure 1: The model is centered at the baseline age, 3-4 years, which is indicated as 0 on the x-axis. The
y-axis indicates total ADHD symptom severity.
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Change in Inattentive Symptom Severity
As shown in Table 4 and depicted in Figure 2, the estimated mean Inattentive Symptom Severity
at 3-4 years was 7.24 (SE=0.46). The average slope or rate of change in Inattentive Symptom severity
was 0.28 (SE=0.06). There was significant estimated variation around the intercept (χ2 = 727.26, df=144,
p<0.01) and the slope (χ2 = 338.81, df=144, p<0.001). This Indicates that the children varied significantly
in their Inattentive Symptom severity at age 3-4 and in their rate of change in Inattentive Symptom
severity over time.
TABLE 4: Change in Inattentive Symptom Severity over time
Results
Fixed Effects

Analysis
Coefficient

SE

T ratio

p

7.24

0.46

15.844

<0.001

0.28

0.06

4.69

<0.001

Level 1 intercept
Intercept
Level 1 linear slope
Intercept

Random Effects

Variance Component

df

χ2

p

Level 1 intercept

24.47

144

727.26

<0.001

Level 1 linear slope

0.54

144

338.81

<0.001

NEURODEVELOPMENTAL GENES ADHD

33

FIGURE 2:
Model 1: Trajectories of Inattentive Symptom Severity from ages 3 to 11 years.

18.76

INN

13.98

9.20

4.43

-0.35
0

2.38

4.75

7.13

9.51

AGE_3

Figure 2: The model is centered at the baseline age, 3-4 years, which is indicated as 0 on the x-axis. The
y-axis indicates Inattentive Symptom Severity.
Change in Hyperactive/Impulsive Symptom Severity
As shown in Table 5 and depicted in Figure 3, the estimated mean Hyperactive/Impulsive
Symptom Severity at 3-4 years was 9.82 (SE=0.53). The average slope or rate of change in
Hyperactive/Impulsive Symptom Severity over time was -0.38 (SE=0.06). There was significant
estimated variation around the intercept (χ2 = 1165.16, df=144, p<0.01) and the slope (χ2 = 393.09,
df=144, p<0.001). This Indicates that the children varied significantly in their Hyperactive/Impulsive
Symptom Severity at age 3-4 and in their rate of change in Hyperactive/Impulsive Symptom Severity
over time.
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TABLE 5: Change in Hyperactive/Impulsive symptom severity over time
Results

Analysis

Fixed Effects

Coefficient

SE

T ratio

p

9.82

0.53

18.40

<0.001

-0.38

0.06

-6.38

<0.001

χ2

p

Level 1 intercept
Intercept
Level 1 linear slope
Intercept

Random Effects

Variance Component

Level 1 intercept
Level 1 linear slope

df

36.32

144

1165.16

<0.001

0.57

144

393.09

<0.001

FIGURE 3:
Model 1: Trajectories of Hyperactive/Impulsive Symptom Severity from ages 3 to 11 years.

18.12

HYP

13.30

8.47

3.65

-1.17
0

2.38

4.75

7.13

9.51

AGE_3

Figure 3: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates Hyperactive/Impulsive Symptom Severity.
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Neuroregulin-1 (NRG1)
Association of NRG1 risk allele with Total ADHD symptom severity over time
As shown in Table 6 and depicted in Figure 4, the estimated mean of Total ADHD symptom
severity at age 3-4 years in children without the NRG1 risk allele was 11.08 (SE=2.00), with a significant
increase of 7.31 (SE=2.25) with at least one NRG1 risk allele (p<0.01). The average slope or rate of
change in Total ADHD symptom severity did not differ by NRG1 risk allele from age 3-4 years to age 11
years (p=0.518). There was significant variation around the average intercept (χ2=1030.20, df=143,
p<0.001) and the average slope (χ2=368.45, df=143, p<0.001) that was not accounted for by the model.
TABLE 6: Association of NRG1 risk allele with Total ADHD symptom severity over time
Results
Fixed Effects

Analysis
Coefficient

SE

T ratio

p

11.08

2.00

5.53

<0.001

7.31

2.25

3.25

<0.01

Intercept

-0.26

0.28

-0.94

0.349

NRG1

0.20

0.30

0.65

0.518

df

χ2

p

105.34

143

1030.21

<0.001

0.98

143

368.45

<0.001

Level 1 intercept
Intercept
NRG1
Level 1 linear slope

Random Effects
Level 1 intercept
Level 1 linear slope

Variance Component
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Figure 4: Association of NRG1 risk allele with Total ADHD symptom severity over time

18.39
NRGBY2 = 0
NRGBY2 = 1

TOTAL

15.94

13.48

11.02

8.57
0

2.38

4.75

7.13

9.51

AGE_3

Figure 4: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates total ADHD Symptom Severity. Red line indicates at least one risk allele for NRG-1,
while the blue is no risk alleles for NRG-1.
Association of NRG1 risk allele with Inattentive symptom severity over time
As shown in Table 7 and depicted in Figure 5, the estimated mean of Inattentive symptom
severity at age 3-4 years in children without the NRG1 risk allele was 4.82 (SE=0.94), with a significant
increase of 2.95 (SE=1.06) with at least one NRG1 risk allele (p<0.01). The average slope or rate of
change in Inattentive symptom severity did not differ by NRG1 risk allele from age 3-4 years to age 11
years (p=0.250). There was significant variation around the average intercept (χ2=689.6.20, df=143,
p<0.001) and the average slope (χ2=333.40, df=143, p<0.001) that was not accounted for by the model.
TABLE 7: Association of NRG1 risk allele with Inattentive symptom severity over time
Results
Fixed Effects

Analysis
Coefficient

SE

T ratio

p

4.82

0.94

5.16

<0.001

Level 1 intercept
Intercept
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2.96

1.06

2.79

<0.01

Intercept

0.11

0.17

0.61

0.544

NRG1

0.21

0.18

1.65

0.250

χ2

p

Level 1 linear slope

Random Effects

Variance Component

df

Level 1 intercept

4.84

143

689.61

<0.001

Level 1 linear slope

0.54

143

333.40

<0.001

Figure 5: Association of NRG1 risk allele with Inattentive symptom severity over time

10.81
NRGBY2 = 0
NRGBY2 = 1

INN

9.31

7.81

6.32

4.82
0

2.38

4.75

7.13

9.51

AGE_3

Figure 5: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates Inattentive Symptom Severity. Red line indicates at least one risk allele for NRG-1,
while the blue is no risk alleles for NRG-1.
Association of NRG1 risk allele with Hyperactive/Impulsive symptom severity over time
As shown in Table 8 and depicted in Figure 6, the estimated mean of Hyperactive/Impulsive
symptom severity at age 3-4 years in children without the NRG1 risk allele was 6.25 (SE=1.11), with a
significant increase of 4.35 (SE=1.26) with at least one NRG1 risk allele (p<0.01). The average slope or
rate of change in Hyperactive/Impulsive symptom severity did not differ by NRG1 risk allele from age 3-4
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years to age 11 years (p=0.958). There was significant variation around the average intercept
(χ2=1078.79, df=143, p<0.001) and the average slope (χ2=392.99, df=143, p<0.001) that was not
accounted for by the model.
TABLE 8: Association of NRG1 risk allele with Hyperactive/Impulsive symptom severity over time
Results
Fixed Effects

Analysis
Coefficient

SE

T ratio

p

Intercept

6.25

1.12

5.60

<0.001

NRG1

4.35

1.26

3.46

<0.01

Intercept

-0.38

0.13

-2.91

<0.01

NRG1

-0.01

0.14

-0.05

0.958

χ2

p

Level 1 intercept

Level 1 linear slope

Random Effects

Variance Component

df

Level 1 intercept

5.82

143

1078.79

<0.001

Level 1 linear slope

0.57

143

392.99

<0.001
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Figure 6: Association of NRG1 risk allele with Hyperactive/Impulsive symptom severity over time

10.60
NRGBY2 = 0
NRGBY2 = 1
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8.61

6.63

4.64

2.66
0

2.38

4.75
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Figure 6: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates Hyperactive/Impulsive Symptom Severity. Red line indicates at least one risk allele
for NRG-1, while the blue is no risk alleles for NRG-1.
Neurotropin-3 (NT-3)
Association of NT-3 risk allele with Total ADHD symptom severity over time
As shown in Table 9 and depicted in Figure 7, the estimated mean of Total ADHD symptom
severity at age 3-4 years in children without the NT-3 risk allele was 16.57 (SE=1.17) with a
nonsignificant increase of 1.45 (SE=1.97) in children with the at least one NT-3 risk allele (p=0.462). The
average slope or rate of change in Total ADHD symptom severity did not differ significantly by NT-3 risk
allele from age 3-4 years to age 11 years. However, there was a trend for rate of change as a function of
NT-3 allele (p=0.104) that can be seen in Figure 7. To better understand the trend in the change of
ADHD over time a secondary analysis indicated significantly higher total ADHD symptom severity for
children with at least one NT-3 risk allele compared to children with no risk NT-3 allele at the final time
point [t(114)=-3.270, p<0.01], but this difference was not evident at baseline. There was significant
variation around the average intercept (χ2=1103.96, df=143, p<0.001) and the average slope (χ2=361.32,
df=143, p<0.001) that was not accounted for by the model.
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TABLE 9: Association of NT-3 risk allele with Total ADHD symptom severity over time
Results

Analysis

Fixed Effects

Coefficient

SE

T ratio

p

16.57

1.17

14.22

<0.001

1.45

1.97

0.74

0.462

Intercept

-0.22

0.13

-1.64

0.102

NT-3

0.34

0.21

1.64

0.104

df

χ2

p

10.61

143

1103.96

<0.001

0.97

143

361.32

<0.001

Level 1 intercept
Intercept
NT-3
Level 1 linear slope

Random Effects

Variance Component

Level 1 intercept
Level 1 linear slope

Figure 7: Association of NT-3 risk allele with Total ADHD symptom severity over time

19.17
NT BY2 = 0
NT BY2 = 1

TOTAL

17.99

16.81

15.64

14.46
0

2.38

4.75

AGE_3

7.13

9.51
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Figure 7: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates total ADHD Symptom Severity. Red line indicates at least one risk allele for NT-3,
while the blue is no risk alleles for NT-3.
Association of NT-3 risk allele with Inattentive symptom severity over time
As shown in Table 10 and depicted in Figure 8, the estimated mean of Inattentive symptom
severity at age 3-4 years in children without the NT-3 risk allele was 7.11 (SE=0.57) with a nonsignificant
increase of 0.36 (SE=0.95) in children with at least one NT-3 risk allele (p=0.703) and the average slope
or rate of change in Inattentive symptom severity did not differ by NT-3 risk allele from age 3-4 years to
age 11 years (p=0.297). There was significant variation around the average intercept (χ2=726.01, df=143,
p<0.001) and the average slope (χ2=334.96, df=143, p<0.001) that was not accounted for by the model.
TABLE 10: Association of NT-3 risk allele with Inattentive symptom severity over time
Results
Fixed Effects

Analysis
Coefficient

SE

T ratio

p

Intercept

7.11

0.57

12.38

<0.001

NT- 3

0.36

0.95

0.38

0.703

Intercept

0.24

0.08

3.12

NT-3

0.13

0.12

1.05

0.297

df

χ2

p

24.64

143

726.01

<0.001

0.54

143

334.96

<0.001

Level 1 intercept

Level 1 linear slope

Random Effects
Level 1 intercept
Level 1 linear slope

Variance Component

<0.01
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Figure 8: Association of NT-3 risk allele with Inattentive symptom severity over time
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Figure 8: The model is centered at the baseline age 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates total Inattentive Symptom Severity. Red line indicates at least one risk allele for NT3, while the blue is no risk alleles for NT-3.
Association of NT-3 risk allele with Hyperactive/Impulsive symptom severity over time
As shown in Table 11 and depicted in Figure 9, the estimated mean of Hyperactive/Impulsive
symptom severity at age 3-4 years in children without the NT-3 risk allele was 9.44 (SE=0.65). There was
a small non-significant increase of 1.07 (SE=1.12) in children with at least one NT-3 risk allele (p=0.342).
The average slope or rate of change in Hyperactive/Impulsive symptom severity did not differ by NT-3
risk allele from age 3-4 years to age 11 years. However, there was a trend for rate of change as a
function of NT-3 allele (p=0.063) that can be seen in Figure 9. To better understand the trend in the
change of ADHD over time a secondary analysis indicated significantly higher total
Hyperactive/Impulsive symptom severity for children with at least one NT-3 risk allele compared to
children with no risk NT-3 allele at the final time point [t(114)=-3.865, p<0.01]. This difference was not
significant at baseline. There was significant variation around the average intercept (χ2=1159.49, df=143,
p<0.001) and the average slope (χ2=382.78, df=143, p<0.001) that was not accounted for by the model.
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TABLE 11: Association of NT-3 risk allele with Hyperactive/Impulsive symptom severity over time
Results

Analysis

Fixed Effects

Coefficient

SE

T ratio

p

Intercept

9.44

0.65

14.418

<0.001

NT-3

1.07

1.12

0.95

0.342

Intercept

-0.46

0.08

-5.80

<0.01

NT-3

0.21

0.12

1.88

0.063

df

χ2

Level

Level 1 linear slope

Random Effects

Variance Component

p

Level 1 intercept

6.03

143

1159.49

<0.001

Level 1 linear slope

0.56

143

382.78

<0.001

Figure 9: Association of NT-3 risk allele in Hyperactive/Impulsive symptom severity over time
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Figure 9: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates total Hyperactive/Impulsive Symptom Severity. Red line indicates at least one risk
allele for NT-3, while the blue is no risk alleles for NT-3.
Brain-derived Neurotrophic Factor (BDNF)
Association of BDNF risk allele with Total ADHD symptom severity over time
As shown in Table 12 and depicted in Figure 10, the estimated mean of Total ADHD symptom
severity at age 3-4 years in children without the BDNF risk allele was 11.36 (SE=2.58) with a significant
increase of 6.42 (SE=2.76) in children with at least one BDNF risk allele (p=0.021). The average slope or
rate of change in Total ADHD symptom severity did not differ by BDNF risk allele from age 3-4 years to
age 11 years (p=0.418). There was significant variation around the average intercept (χ2=1071.85,
df=143, p<0.001) and the average slope (χ2= 370.21, df=143, p<0.001) that was not accounted for by the
model.
TABLE 12: Association of BDNF risk allele with Total ADHD symptom severity over time
Results
Fixed Effects

Analysis
Coefficient

SE

T ratio

p

Intercept

11.36

2.58

4.41

<0.001

BDNF

6.42

2.76

2.33

0.021

Intercept

0.18

0.38

0.49

0.626

BDNF

-0.32

0.39

-0.81

0.418

df

χ2

p

109.09

143

1071.85

<0.001

0.99

143

370.21

<0.001

Level 1 intercept

Level 1 linear slope

Random Effects
Level 1 intercept
Level 1 linear slope

Variance Component

NEURODEVELOPMENTAL GENES ADHD

45

FIGURE 10: Association of BDNF risk allele with Total ADHD symptom severity over time
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Figure 10: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates Total ADHD Symptom Severity. Red line indicates at least one risk allele for BDNF,
while the blue is no risk alleles for BDNF.
Association of BDNF risk allele with Inattentive symptom severity over time
As shown in Table 13 and depicted in Figure 11, the estimated mean of Inattentive symptom
severity at age 3-4 years in children without the BDNF risk allele was 4.83 (SE=1.25) with a significant
increase of 2.72(SE=1.34) in children with at least one BDNF risk allele (p=0.044). The average slope or
rate of change in Inattentive symptom severity did not differ by BDNF risk allele from age 3-4 years to
age 11 years (p=0.782). There was significant variation around the average intercept (χ2=706.97,
df=143, p<0.001) and the average slope (χ2= 339.50, df=143, p<0.001) that was not accounted for by the
model.
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TABLE 13: Association of BDNF risk allele with ADHD Inattentive symptom severity over time
Results

Analysis

Fixed Effects

Coefficient

SE

T ratio

p

Intercept

4.82

1.25

3.87

<0.001

BDNF

2.72

1.34

2.03

<0.05

Intercept

0.34

0.21

1.61

0.110

BDNF

-0.06

0.21

-0.28

0.782

df

χ2

p

23.95

143

706.97

<0.001

0.30

143

339.50

<0.001

Level 1 intercept

Level 1 linear slope

Random Effects

Variance Component

Level 1 intercept
Level 1 linear slope

FIGURE 11: Association of BDNF risk allele with Inattentive symptom severity over time

10.17
BDNFBY2 = 0
BDNFBY2 = 1

INN

8.83

7.50

6.16

4.83
0

2.38

4.75

7.13

9.51

AGE_3

Figure 11: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates total Inattentive Symptom Severity. Red line indicates at least one risk allele for
BDNF, while the blue is no risk alleles for BDNF.
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Association of BDNF risk allele with Hyperactive/Impulsive symptom severity over time
As shown in Table 14 and depicted in Figure 12, the estimated mean of Hyperactive/Impulsive
symptom severity at age 3-4 years in children without the presence of the BDNF risk allele was 6.53
(SE=1.40) with a significant increase of 3.69 (SE=2.44) in children with the presence of at least one BDNF
risk allele (p=0.016). The average slope or rate of change in Hyperactive/Impulsive symptom severity did
not differ by BDNF risk allele from age 3-4 years to age 11 years (p=0.417). There was significant
variation around the average intercept (χ2=1128.72, df=143, p<0.001) and the average slope (χ2= 390.73,
df=143, p<0.001) that was not accounted for by the model.
TABLE 14: Association of BDNF risk allele with in Hyperactive/ Impulsive severity over time
Results
Fixed Effects

Analysis
Coefficient

SE

T ratio

p

Intercept

6.53

1.40

4.65

<0.001

BDNF

3.69

1.52

2.44

0.016

Intercept

-0.16

0.19

-0.82

0.417

BDNF

-0.25

0.20

-1.26

0.210

df

χ2

p

Level 1 intercept

Level 1 linear slope

Random Effects
Level 1 intercept
Level 1 linear slope

Variance Component
35.28

143

1128.72

<0.001

0.32

143

390.73

<0.001
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FIGURE 12: Association of BDNF risk allele with in Hyperactive/ Impulsive symptom severity over time
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Figure 12: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates total Hyperactive/Impulsive Symptom Severity. Red line indicates at least one risk
allele for BDNF, while the blue is no risk alleles for BDNF.
Regulator of G protein signaling 4 (RSG4)
Association of RGS4 risk allele with Total ADHD symptom severity over time
As shown in Table 15 and depicted in Figure 13, the estimated mean of Total ADHD symptom
severity at age 3-4 years in children without the RGS4 risk allele was 15.61 (SE=1.58), with an increase of
2.39 (SE=1.96) with at least one RGS4 risk allele (p=0.223). The average slope or rate of change in Total
ADHD symptom severity did not differ by RGS4 risk allele from age 3-4 years to age 11 years (p=0.378).
There was significant variation around the average intercept (χ2=1101.34, df=143, p<0.001) and the
average slope (χ2= 368.43, df=143, p<0.001) that was not accounted for by the model.
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TABLE 15: Association of RGS4 risk allele with Total ADHD symptom severity
Results

Analysis

Fixed Effects

Coefficient

SE

T ratio

p

Intercept

15.61

1.58

9.91

<0.001

RGS4

2.39

1.95

1.22

0.223

Intercept

0.02

0.17

0.09

0.926

RGS4

-0.19

0.22

-0.89

0.378

df

χ2

p

111.91

143

1101.34

<0.001

0.97

143

368.43

<0.001

Level 1 intercept

Level 1 linear slope

Random Effects

Variance Component

Level 1 intercept
Level 1 linear slope

FIGURE 13: Association of RGS4 risk allele with Total ADHD symptom severity over time
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Figure 13: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates Total ADHD Symptom Severity. Red line indicates at least one risk allele for RGS4,
while the blue is no risk alleles for RGS4.
Association of RGS4 risk allele with Inattentive symptom severity over time
As shown in Table 16 and depicted in Figure 14, the estimated mean Inattentive symptom
severity at age 3-4 years in children without the RGS4 risk allele was 6.71 (SE=0.73), with a
nonsignificant increase of 0.87 (SE=0.94) with the least one RGS4 risk allele (p=0.354). The average
slope or rate of change in Inattentive symptom severity did not differ by RGS4 risk allele from age 3-4
years to age 11 years (p=0.330). There was significant variation around the average intercept
(χ2=724.61, df=143, p<0.001) and the average slope (χ2= 336.94, df=143, p<0.001) that was not
accounted for by the model.
TABLE 16: Association of RGS4 risk allele with change in Inattentive symptom severity over time
Results
Fixed Effects

Analysis
Coefficient

SE

T ratio

p

Intercept

6.71

0.73

9.17

<0.001

RGS4

0.87

0.94

0.93

0.354

Level 1 intercept

Level 1 linear slope
Intercept

0.35

0.09

3.945

<0.001

RGS4

-0.12

0.12

-0.98

0.330

df

χ2

p

25.54

143

724.61

<0.001

0.30

143

336.94

<0.001

Random Effects
Level 1 intercept
Level 1 linear slope

Variance Component
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FIGURE 14: Association of RGS4 risk allele with Inattentive symptom severity over time
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Figure 14: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates total Inattentive Symptom Severity. Red line indicates at least one risk allele for
RGS4, while the blue is no risk alleles for RGS4.
Association of RGS4 risk allele with Hyperactive/Impulsive symptom severity over time
As shown in Table 17 and depicted in Figure 15, the estimated mean of Hyperactive/Impulsive
symptom severity at age 3-4 years in children without the RGS4 risk allele was 8.87 (SE=0.91), with an
increase of 1.55 (SE=1.12) with at least one RGS4 risk allele (p=0.166). The average slope or rate of
change in Hyperactive/ Impulsive symptom severity did not differ by RGS4 risk allele from age 3-4 years
to age 11 years (p=0.533). There was significant variation around the average intercept (χ2=1156.25,
df=143, p<0.001) and the average slope (χ2= 392.51, df=143, p<0.001) that was not accounted for by the
model.
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TABLE 17: Association of RGS4 risk allele with Hyperactive/ Impulsive symptom severity over time
Results

Analysis

Fixed Effects

Coefficient

SE

T ratio

p

Intercept

8.87

0.91

9.73

<0.001

RGS4

1.55

1.12

1.39

0.166

Intercept

-0.33

0.10

-3.263

<0.001

RGS4

-0.08

0.12

-0.62

0.533

df

χ2

Level 1 intercept

Level 1 linear slope

Random Effects

Variance Component

Level 1 intercept
Level 1 linear slope

p

36.05

143

1156.25

<0.001

0.57

143

392.51

<0.001

FIGURE 15: Association of RGS4 risk allele with Hyperactive/ Impulsive symptom severity over time

10.42
RGS4BY2 = 0
RGS4BY2 = 1

HYP

9.24

8.05

6.87

5.68
0

2.38

4.75

AGE_3

7.13

9.51

NEURODEVELOPMENTAL GENES ADHD

53

Figure 15: The model is centered at the baseline age, 3-4 years, which is indicated as age 0 on the x-axis.
The y-axis indicates total Hyperactive/Impulsive Symptom Severity. Red line indicates at least one risk
allele for RGS4, while the blue is no risk alleles for RGS4.
Total Risk Genes
Three out of the four genes showed some evidence of gene effects with NRG-1 and BDNF,
having significant associations with Total ADHD symptoms severity, and NT-3 showing marginal evidence
of a trend toward allele-related differences. To assess the additive role of the risk alleles for the
association with Total ADHD symptom severity, the number of risk alleles for the three genes were
summed to arrive at a sum gene risk variable (possible range 0 -6). Due to low frequencies for risk
values 0 (n=3) and 6 (n=2), those with 0 and 1 risk alleles were combined as were those with 5 and 6 risk
alleles. Table 18 shows the frequency distribution for sum number of risk alleles.
TABLE 18: Distribution of Sum Number of Risk Alleles
Sum Number
of Risk Alleles

N

0-1

16

2

23

3

41

4

44

5-6

21

Note: The 0-1 group is comprised of 3 children with 0 risk alleles and 13 with 1 risk allele. The 5-6 group
is comprised of 19 and 2 children with 5 and 6 risk alleles, respectively.
To determine the association between the sum of risk alleles and Total ADHD, Inattentive and
Hyperactive/ Impulsive symptom severity Pearson correlations revealed significant positive associations
between symptom severity and total number of risk alleles at each time-point (T1-T8) with increasing r
values as children got older (Figure 16). Figures 16 A-H show symptom levels as a function of number of
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risk alleles at each annual time point. Notably, by the latter time points (T7 and T8) there is a clear
linear relation between number of risk alleles and ADHD symptom severity.
FIGURE 16: Correlation of Number of Risk Alleles with Total ADHD symptoms, Inattentive symptoms and
Hyperactive/Impulsive Symptoms at annual time points.
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Figure 17: Total ADHD symptoms as a function of number of risk alleles over time
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Gene x Environment Interaction
To determine whether environmental risk factors for ADHD interacted with gene effects, the
following risk factors were examined using exploratory moderation analyses: maternal gestational
diabetes, maternal substance use (alcohol, tobacco, illicit drug use) during pregnancy and low SES (SES
less than the 10%ile for SES for the sample). Table 19 displays the frequencies for the environmental
risk factors. The following are the only significant results that were obtained in this exploratory analysis.
TABLE 19: Distribution of Sum Number of Environmental risk alleles.
Prenatal Risk Factor

No

Yes

Maternal Gestational
Diabetes

130

15

Maternal Tobacco Use

119

26

Maternal Alcohol Use

113

32

Maternal Illicit Drug Use

135

10

Low SES (<10%)

133

12

Any Prenatal Risk Factor

80

65
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NRG-1 and Early Environmental Risk Factor of Maternal gestational diabetes
Maternal gestational diabetes was examined as a moderator of the relation between NRG-1 and
Total ADHD symptom severity at Time 1. NRG-1 risk alleles and presence of maternal gestational
diabetes were entered in the first step of the regression analysis. In the second step of the regression
analysis, the interaction term between NRG-1 risk alleles and maternal gestational diabetes was
entered, and it explained a significant increase in Total ADHD symptom severity [ΔR2 = 0.084,
F(3,141)=4.314, p<0.01]. Maternal gestational diabetes was a significant moderator of the relationship
between NRG-1 and Total ADHD symptom severity, such that having at least one NRG-1 risk allele and
maternal gestational diabetes increases Total ADHD Symptom severity compared to maternal
gestational diabetes without a NRG-1 risk allele; however, Total ADHD symptom severity was lower
without maternal gestational diabetes and at least one risk allele for NRG-1 compared to both maternal
gestational diabetes risk allele and NRG-1 allele risk and no maternal gestational diabetes and no NRG-1
risk allele (See Figure 18).
Figure 18: Moderation of NRG-1 and Maternal Gestational Diabetes.
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NRG-1 and Early Environmental Risk Factor of Maternal Alcohol Use
Maternal alcohol use during pregnancy was examined as a moderator of the relation between
NRG-1 and Total ADHD symptom severity at Time 1. NRG-1 risk alleles and presence of maternal alcohol
use were entered in the first step of the regression analysis. In the second step of the regression
analysis, the interaction term between NRG-1 risk alleles and maternal alcohol use was entered, and it
explained a significant increase in Total ADHD symptom severity [ΔR2 = 0.087, F(3,141)=4.497, p<0.01].
Maternal alcohol use was a significant moderator of the relationship between NRG-1 and Total ADHD
symptom severity, such that having no NRG-1 risk allele and no maternal alcohol use had lowest Total
ADHD severity compared to maternal alcohol use with and without the NRG-1 risk allele and maternal
alcohol use and at least one NRG-1 risk factor (See Figure 19).
Figure 19: Moderation of NRG-1 and Maternal Alcohol Use.
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NTF3 and Early Environmental Risk Factor of Maternal Tobacco Use
Maternal tobacco use during pregnancy was examined as a moderator of the relation between
NTF3 and Total ADHD symptom severity at Time 1. NTF3 risk alleles and presence of maternal tobacco
use were entered in the first step of the regression analysis. In the second step of the regression
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analysis, the interaction term between NTF3 risk alleles and maternal tobacco use was entered, and it
explained a significant increase in Total ADHD symptom severity [ΔR2 = 0.08, F(3,141)=3.852, p<0.05].
Maternal tobacco use was a significant moderator of the relationship between NTF3 and Total ADHD
symptom severity, such that having at no NTF3 risk alleles and no maternal tobacco use resulted in the
lower Total ADHD severity compared to maternal tobacco use and no NTF3; however, having at least
one NTF3 risk allele and maternal tobacco use was lower compared to no maternal tobacco use and at
least one NTF3 risk allele (See Figure 20).
Figure 20: Moderation of NTF3 and Maternal Tobacco Use.
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BDNF and Early Environmental Risk Factor of Maternal Gestational Diabetes
Maternal gestational diabetes during pregnancy was examined as a moderator of the relation
between BDNF and Total ADHD symptom severity at Time 1. BDNF risk alleles and presence of maternal
gestational diabetes were entered in the first step of the regression analysis. In the second step of the
regression analysis, the interaction term between BDNF risk alleles and maternal gestational diabetes
was entered, and it explained a significant increase in Total ADHD symptom severity [ΔR2 = 0.06,
F(3,141)=3.060, p<0.05]. Maternal gestational diabetes was a significant moderator of the relationship
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between BDNF and Total ADHD symptom severity, such that having no BDNF risk alleles and no
maternal tobacco use resulted in the high Total ADHD severity compared to maternal gestational
diabetes and no BDNF risk alleles; however, having at least one BDNF risk allele and maternal
gestational diabetes was higher compared to no maternal tobacco use and at least one BDNF risk allele.
(See Figure 21).
Figure 21: Moderation of BDNF and Maternal Gestational Diabetes.
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DISCUSSION
ADHD is a neurodevelopmental disorder that is typically first identified in early childhood and
often continues through adulthood (APA, 2013). It is a highly heritable disorder with heritability
estimates in the range of .76 (Faraone et al., 2005). ADHD has been associated with abnormalities in
both neuroanatomical and molecular functioning (Castellanos et al., 2002a; Shaw et al., 2007; Amico et
al., 2001). Driven largely by the effectiveness of psychostimulant medication for treating symptoms of
ADHD, the majority of genetic studies have focused on catecholaminergic and noradrenergic systems
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with weak and inconsistent results (Kustanovich, et al., 2003; Mill et al., 2005; Loo et al., 2003; Ribasés
et al., 2012; Faraone et al., 2005; Gizer, Ficks, & Waldman, 2009). Similarly, serotonin system genes
necessitate further investigation. Beyond genes affecting neurotransmitter systems associated with
ADHD, genes involved in brain growth and development have indicated that some promising areas that
also suggest greater investigation (Mill et al., 2002; Mill et al., 2004; Mick & Faraone, 2008; Hawi et al.,
2013b). Findings from genome-wide association studies have not yet yielded definitive results in
identifying a gene or genes responsible for ADHD (Neale et al., 2010; Hinney et al., 2011; Ebejer et al.,
2013). Theoretically BDNF and glutamate-related genes suggest an association with ADHD, however,
again, findings have been mixed (Turic et al., 2004; Kent et at., 2005).
In response to the limited success of previous research to identify specific genes related to the
presence of ADHD, the current study undertook a novel neurodevelopmental approach in an attempt to
elucidate the genetic basis of ADHD. The study followed a longitudinal sample of preschool-age children
that was evaluated for the presence of ADHD symptoms annually for 8 years. Four genes involved in
neurodevelopment were selected for this exploratory study; NRG-1, NT-3, BDNF, RGS4. Additionally,
information on early environmental risk factors (i.e., maternal gestational diabetes, maternal substance
use - alcohol, tobacco, illicit substance-) was collected to explore moderating relations between genetic
risk and early environmental risk.
The initial modeling of ADHD symptoms over time, independent of other factors, revealed little
group-level change in total ADHD symptom severity with age. However, there was significant individual
variability at the initial preschool age time-point as well as in change in severity over time. In contrast to
total symptom levels, there was a significant increase in inattentive symptom severity with increasing
age and a significant decrease in hyperactive/impulsive symptoms over time. Nevertheless, again, there
was significant inter-individual variability in both the initial level and the slope of change over time in
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both symptom domains. These results were largely expected as the typical course of ADHD is such that
the high prevalence of ADHD symptoms in early childhood tends to decrease through adolescence and
adulthood (Campbell, 1995; Connor, 2002, Halperin, Trampush, Miller, & Newcorn, 2008, Faraone,
Biederman, & Mick, 2006). Symptoms of hyperactivity/impulsivity decrease over time, while symptoms
of inattention are more likely to persist (Biederman, Mick, & Faraone, 2000; DuPaul & Stoner, 2004;
Wolraich et al., 2005).
Among the four genes that were evaluated, three were found to have a notable association with
ADHD symptomatology. Individuals with at least one risk allele of NRG-1 or BDNF had more total ADHD,
inattentive, and hyperactive/impulsive symptoms at preschool age, although the rate of change in
symptom severity over time did not vary as a function of NRG-1 or BDNF genotype. These findings are
consistent with the hypothesis that NRG-1 and BDNF influence the onset of ADHD, but not the trajectory
of ADHD over development from the preschool to school-age years. NRG-1 is associated with finetuning of cortical circuitry and synaptic efficacy, and has an influence on the transcription of multiple
classes of neurotransmitter receptors. These changes in neuronal formation have been associated with
behavioral outcomes (Arnsten, 2006; Yin et al., 2013). BDNF is involved in neurodevelopment, synapse
regulation and synaptic plasticity, modulates synaptic transmission, and is associated with behavioral
disorders, such mood disorders and schizophrenia (Fernandes et al., 2014). BDNF also demonstrates a
protective role with neuronal homeostasis and is protective against neuronal insults. Both are
associated with synaptic plasticity and long-term functionality. Changes in neurotropic activity during
brain development can results in neuronal dysfunction which can lead to disordered behavior. It was
hypothesized that both NRG-1 and BDNF would be associated with ADHD symptoms at preschool and
associated with the persistence of ADHD symptoms until school age. Our results supported the onset of
ADHD symptoms being associated with NRG-1 and BDNF, but not the persistence of ADHD, at least prior
to puberty.
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In contrast, NT-3 genotype did not significantly relate to ADHD onset or trajectory. However, a
trend emerged suggesting that NT-3 might influence the trajectory of total ADHD symptoms and
hyperactive/impulsive symptoms in particular. Although NT-3 has been identified as regulating CNS
neurogenesis during early development, results suggest that NT-3 may impact ADHD symptoms later in
development. Finally, RGS4 risk alleles did not impact ADHD onset or trajectory. Although, we
hypothesized that RGS4 allelic variability would relate to ADHD symptoms onset and trajectory, out of
the four genes evaluated it was the one with the least substantial theoretical support.
Collectively this information suggests a role for three of the neurodevelopmental genes
examined, with their effects primarily on the onset of ADHD symptoms. Although, this was an
exploratory study, it was hypothesized that these genes would have an impact on the trajectory of
ADHD. Apart from, NT-3, which showed a trend such that it impacted ADHD later in development, the
other two genes only related to early onset at preschool age. One possible explanation is that these
neurodevelopmental genes have their largest impact on the early onset ADHD symptoms and other
genes have greater contribution to influencing ADHD symptoms in late school age (Pingault et al., 2015).
Alternatively, individuals with NT-3 risk allele are more likely to grow into their genes in late school age
and early adolescence.
Although the results indicated an association such that individual genes related to ADHD
symptomatology, it is highly likely that ADHD is not a result of a few genes, but rather a collection of
genes with small effect size that contribute to the onset and/or the persistence of the disorder. To
examine the collective nature of multiple genetic risks, the next analysis combined total number of
genetic risk alleles. It was expected that with more genetic risk one would be more likely to have an
increase in ADHD symptoms (Rutter, 1987). As proposed, the number of genetic risk alleles was
associated with increased total ADHD, inattentive, and hyperactive/ impulsive symptoms at each time
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point, such that the more risk alleles an individual had the more ADHD symptoms. Notably, the strength
of the association between number of risk alleles and ADHD symptoms increased with increasing age.
This suggests an additive effect of genetic risk on ADHD symptoms at onset and over time, and raise the
possibility that as children get older, genetic influences on ADHD severity get stronger as environmental
influences diminish. Although the combination of risk alleles from the three genes assessed was
associated with ADHD, it is very likely that many more genes, not only the ones selected for this study,
are involved as there continues to be significant unaccounted variability.
Exploratory Moderation Analyses
Exploratory analyses into early environmental factors were conducted to evaluate gene-byenvironment interactions and to explore the unaccounted-for variability. The influence of maternal
gestational diabetes and maternal substance use during pregnancy was mixed. It was hypothesized that
early environmental risk factors would moderate ADHD symptoms and provide further explanation for
individual variability in symptomatology. Only a few of several analyses conducted yielded significant
findings, and some are difficult to interpret.
Significant moderation was found between NRG-1 and two maternal risk factors; gestational
diabetes and maternal alcohol use during pregnancy. Yet, the pattern of the interaction differed
between these two environmental risk factors. Maternal gestational diabetes was unrelated to ADHD
symptom severity in those without an NRG-1 risk allele. However, among individuals with an NRG-1 risk
allele, those with and without maternal gestational diabetes had the highest and lowest levels of ADHD
symptoms, respectively. As stated above, the nature of the interaction was different for maternal
alcohol use during pregnancy. Children of mothers who drank alcohol during pregnancy had elevated
levels of ADHD symptoms irrespective of NRG-1 risk, as did those with an NRG-1 risk allele irrespective
of maternal alcohol use. Those without the genetic (i.e., NRG-1 risk allele) and environmental (i.e.,
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maternal alcohol use during pregnancy) risk factors had significantly lower levels of ADHD symptoms as
compared to the other three groups. Thus, it appears that effect of gestational diabetes on the
offspring’s neurodevelopment is dependent upon NRG-1 risk status. In contrast, maternal alcohol use
during pregnancy has negative effects irrespective of genetic status.
A significant interaction also emerged between NT-3 risk status and maternal tobacco use
during pregnancy, although the nature of the interaction was surprising and interpretation of this
finding is less clear. NT-3 risk and maternal tobacco use resulted in lower levels of ADHD symptoms
compared to those with the genetic risk but no maternal tobacco use. Overall, the nature of this
interaction suggests that NT-3 risk is reduced in those whose mothers smoked during pregnancy.
Finally, significant moderation was found between BDNF and maternal gestational diabetes.
Here the nature of the interaction was such that BDNF risk had a minimal impact when gestational
diabetes was not present. However, among those with gestational diabetes, elevated ADHD symptom
levels were seen only in those children who had a BDNF risk allele.
Taken together it appears that maternal gestations diabetes is associated with elevated levels of
ADHD symptoms only in youth at elevated genetic risk (via NRG-1 and/or BDNF), consistent with a geneby-environment interaction. In contrast, maternal alcohol use during pregnancy may moderate the
influence of NRG-1 on ADHD symptoms. Although the environmental risk analysis was exploratory, it
was expected that environmental risk factors would moderate genetic risk. In contrast, the interaction
involving NT-3 and maternal tobacco use is more difficult to explain and understand. It appears that
maternal smoking may mitigate the risk associated with NT-3. While the results for the impact of
environmental factors are mixed, these analyses are exploratory and may reflect chance findings given
the large number of analyses conducted. Even though the analyses are exploratory and limited these
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areas of investigation could yield valuable information in understanding the impact of suboptimal early
prenatal development brain.
Limitations
As this was a small pilot study there were several limitations. The most apparent limitation is
the small sample size. As stated previously, the current sample was selected from a slightly larger
longitudinal study. Compared to contemporary genetic studies the sample size is substantially smaller.
However, despite the small sample size, there were some significant findings with three out of the four
genes studied. Although this does not exclude the chance of random findings, it does suggest that a
potential avenue of further research. Environmental risk factors information was collected at the initial
evaluation time point, but was still dependent on retrospective recall. Further, the information that was
used in the analysis was binary (i.e., endorsement or lack of endorsement). Greater sensitivity might
have emerged had dimensional measures of environmental risk been employed. Additionally, the
binary nature could lead to uncaptured variability between individuals. For example, there could be a
difference in outcome depending on the prenatal developmental time point the substance was used, or
the frequency and extent of the substance that was used. With maternal gestational diabetes, there
could be variability in management of the disease and ultimately variability on the impact on the
developing fetus and in turn impacting neurological development. Additionally, the low frequency of
endorsement of maternal substance use limited the use of some of the analysis. A sample with greater
proportion of maternal substance use including more detailed information on the timing of exposure
during pregnancy, and the impact of varying amounts of fetal exposure, would allow more depth of
analysis such as time sensitivity and dose dependent moderation. Finally, it is possible that respondents
were not completely forthcoming with information, particularly as related to more sensitive topics such
as substance use during pregnancy.
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Despite clear evidence from behavioral genetic studies for the importance of genes in the
etiology of ADHD, the elucidation of specific genes has not been as fruitful or rewarding as expected.
Much of the field has moved in the direction of genome-wide analyses, and some genetic markers are
beginning to emerge (Franke et al., 2012; Elia et al., 2012; Sánchez-Mora et al., 2015). However, such
analyses require extremely large samples and are generally not helpful for identifying gene-byenvironment interactions because it is difficult, if not impossible to acquire individualized environmental
data from such large samples (Moore, 2017). This study offers a somewhat different approach to
studying and understanding the etiology of this neurodevelopmental disorder by focusing on genes
involved in neurodevelopment.
The current study was limited in both the breadth and depth of possible genes involved in the
onset and the persistence of ADHD. There are many more genes that are involved in
neurodevelopmental processes that affect aspects of neural development, which impact neural
pathways, and ultimately influence behavior that suggest additional avenues of investigation. Even
among the genes evaluated, only single nucleotide polymorphisms were evaluated and yet there are
possible alternative gene variants even in the genes evaluated that can impact ADHD symptomatology.
One clear area of further research is to explore the cumulative nature of neurodevelopmental risk
alleles of additional neurodevelopmental genes. Another area to explore is the impact of these genes
on ADHD symptoms in later adolescence and early adulthood, where genes involved in the maturation
of the cortex exert the most impact and can differentiate those that continue to experience functionally
impactful symptoms of ADHD. Further, the current study did not have the power to properly evaluate
the impact on males versus females. Finally, and possibly most importantly, due to the exploratory
nature of the study, these findings need to be replicated. Genetic findings, especially with a limited
sample require further analyses.
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Future Directions
Additional routes of further research can include environmental factors. The current study
looked at the prenatal environmental risk factors to identify additional areas that can impact individual
symptomatology of ADHD. Maternal alcohol use, tobacco use and maternal gestational diabetes were
identified as possible factors. In addition to these factors, physical abuse, child neglect, maternal
exposure to stress, trauma, poor nutrition, premature birth, perinatal complications, very low birth
weight, early hypoxic episodes, and exposure to environmental toxins can also be explored as risks to
early neurologic development. Early environmental factors can also have a role in the expression of
these genes. Further exploration of gene production will provide better understand of gene and
environmental interactions. More accurate measurement and assessment of environmental factors can
contribute to the understanding of cumulative risk on neurodevelopment.
With the understanding that the developmental trajectory of ADHD varies in presentation and
persistence over development; better understanding of the factors that impact ADHD symptomatology
can give direction to those treating individuals with the disorder in a more personalized way. It is
possible that in the future genetic profiles could identify individuals at risk for the disorder prior to
preschool age and provide information on the possible severity and persistence over development. This
information can be used to structure early optimal behavioral treatment and symptom management.
Genetic profiles may also suggest optimal pharmacological interventions.
Conclusions
The findings of this study suggest a possible fruitful new direction into both the understanding
of the etiology of ADHD across development and an alternative approach into exploring
neurodevelopmental genetic risk factors. Going forward this study suggests an approach that considers
the onset and persistence of ADHD symptoms and identifies those genes that undermine optimal
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neurodevelopment. Lastly, the study also suggests incorporating early environmental factors that can
negatively impact brain development and how these factors, in coordination with genetic factors,
manifest in psychopathology. Although the current study focused on ADHD symptomatology,
investigations into other neurodevelopmental disorders, such as Autism Spectrum Disorder, may also
benefit from this approach.
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Appendix

Table 1: Summary of genetic results
Gene
DRD4

DRD5

Type of Study

Results

Case control

7 –repeat – inconsistent findings, no single significant findings

Case control
Meta-analysis
Family-based
Meta-analysis
Case control

7 –repeat - OR = 1.9 (p < 0.001)

Case control

148-bp allele – association
136-bp and 146-bp alleles – no association
148-bp allele – association
136-bp and 146-bp alleles – no association
2/4 studies found 148-bp allele – association

Family based
Meta-analysis

7 –repeat - OR = 1.4 (p = 0.02)
2 and 4-repeat allele – not significant

DRD2

Case control

DRD1

Case control

DAT1

Case control

A1 allele – inconsistent association
A2 allele – association with hyperactivity and impulsvity
association with DRD1 in childhood combined type ADHD, but
not in adulthood ADHD
two SNPs associated with ADHD (rs4532, rs265981)
No association with ADHD

DBH

Case control

A1 and A2 allele – significant but weak association

TH

Case control

No association

DRD3

Case control

No association

COMT

Case control

Inconsistent association (Val108Met polymorphism)

MAO-A

Case control

SLC6A2/NET1

Case control
Meta-analysis
SNP studies

ADRA1A

Case control
Meta-analysis
Case control
Meta-analysis

30-bp tandem repeat of the promoter region of the gene in two
ethnic populations
Association
No association
rs3785157 – association in two studies, not replicated
rs998424 – association in one study, not replicated
rs3785143 and rs11568324 – association in one study
Association
No association
Association
No association

ADRA1B
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SLC6A2/NET1
and ADRA1B
ADRA2A

Case control

multi SNP haplotypes association

Case control

Serotonin
Receptor Genes

Case control study

G-1291C allele at the promoter region, not replicated
G-1291C association with inattentive subtype
HTR1B receptor G861C allele with ADHD – association, not
replicated
HTR2B receptor T102C and G1438A – not associated
HTR1E receptor – no association
HTR3B receptor – no association
Association with His452Tyr allele and not the T102C allele, not
replicated
5-HTTLPR polymorphism - 2/4 found an association

Family based
Serotonin
transporter

Case control
Family based

TPH

Family based

SNAP25

Family based
Meta-analysis
Family based

BDNF

Case control

Glutamate

Family based

5-HTTLPR polymorphism – one study found an association
Another study found an association with combined type
Third study found no association
2 studies did not find an association
1 study - rs1843809 T-allele, rs1386497 A-allele, and rs1386493
C-allele – association
2nd study - rs1843809 A-allele and rs1386493 G-allele –
association
T1069C and T1065G – association, not replicated
T1065G association with ADHD
rs66039806-C, rs362549-A, rs362987-A, rs362998-C alleles,
rs363020, rs362567- association, not all replicated
Val66 allele parental transmission and association of ADHD, not
replicated
No association with 20 SNPs
GRIN2A , Association, not replicated
Haplotype –weak association
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